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Thesis Overview 
The aim of this thesis is to describe how the use of pharmacokinetic and 
pharmacodynamic techniques can provide a better understanding of the optimal use of 
antimicrobial agents. In vivo animal experimental models and clinical PK-PD datasets for 
three systemically administered antifungal agents, isavuconazonium sulfate (active 
moiety isavuconazole), micafungin, and VL-2397, are used to accomplish this goal. 
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Chapter 1 Introduction  
Pharmacokinetic (PK)-pharmacodynamic (PD) experiments in the development of the 
antimicrobial therapy 
Pharmacokinetic (PK)-pharmacodynamic (PD) techniques have been developed to 
answer important questions regarding the proper use of drug therapies. The techniques 
offer opportunities to optimize the use of antimicrobial compounds. The field continues 
to broaden providing an enhanced understanding of the amount and duration of a specific 
compound required to treat an infection. PK-PD is used to increase the likelihood of 
better patient outcomes, decrease resistance development, and minimize the risk for 
antibiotic drug development programs because of the better optimization of regimens.  
The intrinsic factors that play a role in the ability of a drug to affect an invading 
pathogen, and ultimately patient outcomes include the dose, duration of therapy, ability 
of the drug to reach infected tissues, and the mechanism of action (1). Host factors (e.g. 
immune status) are also significant but independent factors. PK-PD experimental 
techniques operate by illustrating important relationships between how the body affects 
the drug (PK) in correlation with how the drug affects the target pathogen (PD). 
Regulatory authorities increasingly recognize the importance of PK-PD techniques 
and require these data are included in marketing applications. As recent as July 2016, the 
EMA issued the “Guideline on the use of pharmacokinetics and pharmacodynamics in the 
development of antimicrobial medicinal products” (EMA/CHMP/594085/2015) 
(http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/
WC500210982.pdf). This guidance outlines important deliverables for the applicant 
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related to PK-PD data. Specifically, the guidance describes the microbiology data 
required, the need to identify the PD indices and PD targets, the clinical PK data 
recommended to support the PK-PD analysis, the probability of target attainment (PTA) 
analysis to support the dosage regimen, and exposure-response analyses. Importantly, the 
guidance describes the extent to which results from PK-PD analyses can replace clinical 
data. The FDA does not have guidance that addresses these more contemporary PK-PD 
issues, although the NIH is seeking to understand these issues further [NIH workshop in 
June 2017]. 
Importance of in vivo and in vitro experimental models. Traditionally, experimental 
models using laboratory animals that mimic human disease have been used to 
characterize pharmacological efficacy and safety prior to clinical use. In antimicrobial 
drug development, these experiments have been shown to be highly predictive of the 
human disease and efficacy (2). These experimental models have brought forth an 
increasing ability to further explore exposure-response relationships for many drug-bug 
combinations, specifically, detailing the time-course of drug exposure, penetration of 
drug to the site of infection and the ultimate antimicrobial effect (1).  
More recently, in vitro dynamic experimental models such as hollow fiber used 
primarily for antibacterial work or in vitro dynamic models used for pulmonary infections 
caused by filamentous fungi have furthered our ability to explore larger dose ranges and a 
more diverse spectrum of organisms including resistance organisms (3, 4). Treatment of 
infections caused by Aspergillus spp. and rare filamentous fungi, treatment of infections 
in rare populations with distinct pathogenesis (e.g. neonatal candidiasis) and in difficult 
to penetrate body sites (e.g. CNS) are difficult to study in clinical trials. A detailed 
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understanding of exposure-response relationships bolsters the selection of dosage 
regimens that are safe and effective and increases the likelihood of studying the optimal 
dose initially. Further, PK-PD data better inform and provide the basis for treatment and 
prevention of antimicrobial resistance, determination of the requirement for therapeutic 
drug monitoring, and decision support for establishing in vitro susceptibility breakpoints. 
Using Biomarkers in PK-PD: Use of Galactomannan as Prognostic Tool in Invasive 
Aspergillosis  
Invasive aspergillosis (IA) causes significant morbidity and mortality (5, 6). 
Treatment is complicated by the limited number of antifungal classes and agents, 
antifungal drug toxicity, an incomplete spectrum of antifungal activity, and increasing 
incidence of antifungal resistance (7-11). Patient management is complicated. The 
diagnosis is not always confirmed, which delays treatment, and treatment duration is 
guided subjectively without information on appropriate duration of therapy. Bedside 
assessment of response is tough. Lack of specificity in the clinical signs and symptoms, 
variability in the radiological exams during treatment, which makes the assessment hazy, 
and clinical response to therapy occurs over weeks-to-months.  Ideally, a tool that could 
be used at the bedside or in a more objective manner to follow response would 
significantly improve the routine care of patients with IA. In addition, such a tool would 
significantly enhance the outcome assessment, duration, and cost of clinical trials of new 
antifungal drugs. The biomarker such as galactomannan (GM) may be an important way 
clinical trials for invasive aspergillosis can be expedited. 
Galactomannan is a polysaccharide present in the cell wall of Aspergillus spp., and 
some other fungi (12).  It is released by hyphae, which are the biologically invasive forms 
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of filamentous moulds. A commercial double-sandwich enzyme-linked immunosorbent 
galactomannan assay (ELISA) is available to detect Aspergillus GM antigen in body 
fluids.  The assay uses a monoclonal IgM obtained from rats following challenge with 
mycelial extracts from Aspergillus spp. (12, 13). It has been successfully used to aide in 
the speed and accuracy diagnosis of invasive aspergillosis (IA) allowing for earlier 
recognition of disease compared to conventional methods. Since its implementation in the 
clinic as a diagnostic tool, GM has been used in experimental models to measure 
therapeutic response (14-16). Several clinical studies describe the prognostic value of 
GM (17). A decline in GM or GM negativity has been linked to clinical outcomes, eg, 
survival or successful clinical response, was reported to correlate in patients that do well 
(18-21). 
Structure and biology of galactomannan. The polysaccharide cell wall component of 
GM has a branched structure with a linear α mannan that has a repeating mannose 
oligosaccharide unit [6Manα1-2Manα1-2Manα1-2Manα1] and short chains of β (1,5) 
galactofuranose residues (12). It is released from fungal hyphae during growth in the 
extracellular material (i.e. ethanol-precipitable material) as part of the chemical 
breakdown in the cell as the hyphae grow (i.e. a metabolic event) and not a result of 
mycelial lysis. Organisms that are known to release GM include Aspergillus spp., 
Fusarium spp., Scedosporium spp., Alternaria spp., Histoplasma spp. and Penicillium 
spp. (22-26). GM can be detected in serum and other bodily fluids such as 
bronchoalveolar lavage (BAL) and cerebrospinal fluid (CSF), and has been used to 
support a diagnosis of IPA and cerebral aspergillosis, respectively. There are no 
established cut-offs values for GM from matrices outside of the serum. 
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Aspergillus releases GM as part of recycling process of the cell wall during hyphal 
growth. GM measurement is achieved by using sandwich enzyme-linked immunosorbent 
assay (ELISA), which detects galactomannan antigen via binding to monoclonal antibody 
and the formation of a monoclonal antibody-galactomannan-monoclonal 
antibody/peroxidase complex. A spectrophotometer is used to determine the absorbance 
(optical density; OD) of the samples. Serum samples are considered positive when the 
GMI (OD) is ≥ 0.5 and negative when < 0.5. GMI has no units and if expressed as a ratio 
of the OD value of the sample to the OD value of a standard sample containing 1 ng of 
GM. The test has a lower limit of detection of 1 ng/mL. GM is utilized primarily as a 
diagnostic test; however, evidence is increasing for its value as a prognostic test. 
Relevance of GM in the pathogenesis of IA. The release of GM correlates with the 
progression of disease and its resolution in experimental models of IA (4). Clear trends 
are seen when an infection responds to effective therapy. Levels of GM in the serum 
correspond to the timing of tissue invasion and are an integral measure of the mass of 
viable invading organisms. GM can be detected as early as 12 hours post inoculation, 
which corresponds with hyphal invasion as determined using histopathological 
techniques (4, 27).  Serum GM levels continue to increase and eventually reach a plateau 
as the ELISA assay is saturated and/or there is capacity limitation of fungal growth 
following exhaustion of available nutrients.  BAL GM concentrations are typically high 
throughout the course of infection in experimental models. Presumably this reflects 
hyphal growth in the airways and does not necessarily imply invasion.  The presence of 
GM implies the presence of hyphae rather than conidia (the latter do not liberate GM) 
and in this sense GM provides slightly different information than culture and PCR from 
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samples from the airways, which may not necessarily distinguish the different fungal 
morphotypes. 
The discordant kinetic profiles of GM in serum and BAL suggest that the GM does 
not transverse the alveolar-capillary bilayer or other biological barriers to any great 
extent.  Presumably its molecular weight (~20 kDa) (12) prevent transgression even in 
the context of significant tissue disruption.  The appearance of GM in the circulation 
therefore represents angioinvasion rather than simple diffusion into the bloodstream from 
contiguous areas of infection. 
Early in vivo studies suggest that the major pathway for Aspergillus GM clearance 
from the bloodstream is renal excretion and hepatic metabolism based on uptake by 
macrophage mannose receptors (28). The majority of the renal excretion is rapid, within 
the first 24 hours. Detection of GM in the urine of patients with IA has been reported 
(29). 
GM is a Complementary Measure of Fungal Burden in Experimental Models of 
IA. The traditional measure of tissue burden obtained by plating serial dilutions of tissue 
homogenates to agar does not (in general) provide a useful measure of fungal burden.  
There are several reasons for this.  In some experimental models, sampling at early time-
points may not enable conidia (environmental forms) that are used to initiate infection to 
be distinguished from hyphae (tissue invasive forms).  Detection of both morphotypes 
leads to a positive culture or PCR signal and quantification of fungal burden even though 
it is only hyphae that are biologically relevant in this situation.  An accurate 
quantification of fungal burden is further complicated by the growth patterns of 
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Aspergillus, which extends via hyphal elongation with indistinguishable cellular units and 
additional branching from older and newer segments (30).  Tissue homogenization and 
quantitative counts do not enable an accurate estimate of the fungal biomass.  Propagules 
are either incompletely separated or more vigorous grinding leads to complete hyphal 
disruption and subsequent fungal death.  In either situation log10CFU/g is an inaccurate 
reflection of the underlying fungal biomass and neither reflects important events in the 
pathogenesis nor response to antifungal therapy. 
Despite these potential limitations, fungal burden (log10CFU/g) from the rabbit model 
provides a crude, but reliable readout to assess a variety of antifungal agents (with the 
possible exception of the echinocandins).  In this model sampling occurs late in the 
treatment period and is probably not confounded by the presence of conidia.  In other 
model systems, log10CFU/g is completely non-informative.  In any context log10CFU/g is 
often too imprecise to construct detailed dose-exposure-response relationships. 
Other non-culture techniques used to estimate fungal burden in experimental models 
after infection with Aspergillus spp. include polymerase chain reaction (PCR) to measure 
of the amount of fungal DNA in tissues, or assays that measure the amount of fungal cell 
wall components such as chitin and 1,3-β-D-glucan. Each method has advantages and 
limitations (see Table 1).  
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Table 1 Comparison of Experimental Techniques to Measure Aspergillus fungal burden  
Method Description Advantage Disadvantage 
CFU Counting of single organisms by plating 
of serial dilutions of a suspension; using a 
hemacytometer 
Simple, inexpensive 
 
Homogenisation by mechanical 
dispersion can disrupt the count by 
breaking the hyphae into smaller 
pieces causing either fewer viable 
fragments or increase in viable units 
Chitin-assay Measure of the amount of chitin by KOH 
extraction and colorimetric assay of an 
aldehyde derivative of chitosan 
Measuring content in hyphae not conidia since chitin is 
not present in conidia 
Does not distinguish between viable 
and non-viable hyphae, nor viable but 
ungerminated conidia can go 
undetected. 
PCR Measure either 18S rDNA (present in the 
genome in 100 per nucleus) or FKS1, 
single-copy gene 
Better accuracy than CFU depending on the tissue 
especially in the first few days after inoculation 
Does not distinguish between viable 
and non-viable organisms. Use of 18S 
rDNA can over-estimate fungal 
burden given the multinucleic nature 
of Aspergillus spp. 
High cost, complex 
Lateral-Flow Detects the presence of Aspergillus- Rapid detection of the presence Aspergillus spp. within No quantitative details of the amount 
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Device specific MAb (JF5) (31) an immune-chromatographic lateral-flow device. 
Measure of growing Aspergillus 
of organisms 
Electronic nose Detects volatile organic compounds 
(VOCs) using an “electronic nose” which 
is an artificial olfactory system to 
discriminate odors using an array of 
sensors. (32) 
Rapid detection of presence of Aspergillus spp. in the 
airways 
No quantitative details of the amount 
of organisms 
Only pertinent to pulmonary infection 
Abbreviations: CFU: colony-forming units; KOH: potassium hydroxide; PCR: polymerase chain reaction; rDNA: recombinant deoxyribonucleic acid 
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GM and Experimental Pharmacodynamics. GM is increasingly used in 
pharmacodynamic models of IA to estimate dose-exposure-response relationships.  The 
advantages of this biomarker include a rapid response to antifungal therapy, the fact it is 
readily quantifiable, the availability of a commercial kit and validation in a variety of 
model systems.  The disadvantages include a relatively narrow dynamic range, relatively 
high expense, and large inherent variability.  
GM as a Clinical Biomarker with Prognostic Value. Clinical evidence supporting 
the utility of GM as a prognostic tool for patients with IA has steadily accrued over the 
past two decades.  The earliest suggestion that GM might be a valuable biomarker for 
measuring therapeutic response in patients was established in 1997.  However, the 
general utility of exploiting the prognostic value of GM was initially limited by the 
relatively high number of false positive results (33). Early case reports describe 
increasing GMI during treatment in individual patients with poor outcomes. (34-36). 
Evidence of GM’s Prognostic Value from Case Series and Clinical Studies. The 
first clinical study conducted early in the use of GM was limited by sparse sampling. 
However, a trend of increasing GM in patients that subsequently died was evident (33).  
Subsequently, nine separate studies representing 661 patients and one meta-analysis 
covering 27 studies and 257 patients that evaluated the utility of GM assay to monitor 
therapeutic response have been reported. Eight studies largely focused on patients with 
hematological malignancy, while one included patients with COPD. The studies evaluate 
responses in patients with proven, probable, possible, or suspected invasive aspergillosis 
and one study included patients with invasive fusariosis. One study assesses the use of 
serial GM in pediatric patients and the associated exposure-response relationship. Each 
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study demonstrates the potential usefulness of serial GM measurements in IA patients by 
showing that GM generally increases (or does not decline) in patients that fail treatment 
or ultimately die. 
Correlation with traditional measures of response to therapy. Changes in GMI from 
the time of diagnosis or baseline correlate significantly with various outcome measures 
including clinical outcome defined by EORTC/MSG criteria at 6 and 12 weeks, mortality 
at 12 weeks, and with autopsy findings (18-21). The GMI-based outcome proposed from 
these correlations is defined as GMI negativity (OD < 0.5) for at least 2 weeks after the 
first positive value without new pulmonary or extra-pulmonary lesions and lack of 
findings of IA on autopsy (18, 21). 
GMI-based outcome criteria. Several outcome measures for GM are possible and 
include time to GMI negativity, time to a certain percent reduction in GMI, rate of 
decline (or GM decay), area under the GMI time curve, or time to negativity. However, 
with these possibilities, a degree or quantification of GMI change aside from negativity 
has yet to be defined. The only criterion that is currently used is GMI negativity (OD < 
0.5) for a period of 2-weeks without pulmonary or extra-pulmonary lesions. An autopsy 
may be necessary to definitively exclude IA. While this GM outcome provides excellent 
correlation to clinical measures of response, the average time to negativity in one study 
was 21 days in patients who ultimately responded to antifungal therapy. An earlier 
intervention may be preferable (18). The rate of decline of GM (i.e. slope) at 1 week after 
diagnosis of IA has also been proposed as a surrogate for clinical outcome (i.e. for 6- and 
12-week all-cause mortality) based on increasing hazard ratios with each unit increase 
from diagnosis (37). This GM outcome measure is more practical than the GM outcome 
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of negativity for 2 weeks duration as it utilizes an early time point and relatively simple 
calculation to guide response. 
Significant increases in GM after each week of therapy are associated with ultimate 
treatment failure (38-40). Most studies report a strong correlation of survival with 
decreases GMI (e.g. GMI normalization to readings <0.5) (19, 21). However, at least one 
study reports that changes from baseline to week 2 are not predictive of 12-week survival 
(39). The reason is most likely because mortality by 12 weeks is more often driven by 
underlying co-morbidities as opposed to the fungal infection. 
Other fungal biomarkers, such as, the 1,3-β-D-glucan (BDG) assay (Fungitell™), are 
used in the clinic. BDG detects the cell wall component, (1,3)-β-D-glucan, which is 
present in most fungi, and therefore, not specific to Aspergillus spp. This assay could 
potentially be used in conjunction with GM as a prognostic tool after IA is diagnosed. 
However, there is little data available showing correlation to clinical outcome outside of 
experimental models (27, 41). One study suggests that decline in the mean time-weighted 
averages of BDG plus GM from baseline to week 2 of therapy is associated with 6-and 
12-week survival (40). 
Using GM to individualize antifungal therapy. The time course of GM in an 
individual patient may be affected by antifungal drug exposure (pharmacokinetics), the 
MIC of the invading fungal pathogen, the immune status of the host, and the underlying 
high fungal burden (pharmacodynamics).  Therapeutic drug monitoring of antifungal 
agents has traditionally focused on achieving plasma drug exposure targets.  The 
pharmacodynamic responses to antifungal therapy have typically been less formal.  
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However, GM can potentially be used to guide antifungal therapy at an individual level.  
The time course of GM may provide a guide as to the intensity of antifungal therapy that 
is required to achieve a favorable clinical outcome.  Patients with high unremitting GM 
concentrations receiving a standard antifungal regimen should have the dosage increased, 
the drug changed or a combination of agents used.  The necessary mathematical models 
that explicitly link dosage, plasma drug concentrations and circulating GM provide a way 
that therapy can be individualized to move the biomarker rather than merely achieving a 
target plasma concentration, which may not be optimal for the patient.  
A further possibility that is enabled by GM is an estimate of the pharmacodynamic 
targets required for a successful outcome.  Traditionally, this pharmacodynamic measure 
has been the MIC and drug exposure (e.g. AUC) has been optimized with reference to 
this in vitro measure of potency.  A common problem in clinical mycology is that the 
organism (and therefore the MIC) is not available- it is quite uncommon for patients to 
have positive cultures.  The use of linked PK-PD models with GM as a real-time 
pharmacodynamic readout provides alternative measures of in vivo potency that can be 
used to optimize drug exposure.  The EC50 is the concentration of antifungal drug that is 
required to induce half maximal antifungal activity.  The AUC can be optimized in 
relation to the EC50 to secure a favorable outcome.  This idea was explored in a recent 
relatively small study in pediatric patients receiving voriconazole (42).  In these children, 
an (AUC:EC50)/15.4 is significantly associated with terminal GMI (GMI value at the end 
of therapy). When the ratio is > 6, the terminal GM tends to be lower.  However, survival 
did not correlate with the AUC:EC50.  Further work is ongoing in this area. 
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PPK Models Can Be Used to Enhance Understanding of PK in Different Populations 
and Disease States 
Rarely when an antimicrobial agent is initially brought to market are the PK data vast 
enough to understand all possible scenarios, such as those potentially impacting 
exposures for different infection types ad sites of infection, underlying diseases, and 
specific patient conditions such as obesity and gastro-intestinal disruption (mucositis). 
The data that is available focuses on the primary patient population for the initial labeled 
indications. Therefore, population PK modeling can be used to explore factors impacting 
exposure in these different populations and explore the PD impact as well. 
Isavuconazole  
Isavuconazonium sulfate is the water-soluble prodrug of the triazole antifungal agent 
isavuconazole and is available in cyclodextrin-free intravenous (i.v.) and oral (p.o.) 
formulations (43). The pharmacokinetics have been characterized from sub-studies 
embedded in clinical trials (44-47). Many of the pharmacokinetic (PK) analyses initially 
reported are limited to healthy volunteers and patients treated for IA. There is a paucity of 
data regarding the population pharmacokinetics (PPK) in patients with a variety of 
invasive fungal infections, clinical conditions, and underlying diseases. The pivotal 
clinical trials included more than 400 patients with >60% with hematological 
malignancies or other conditions that required intensive chemotherapy and the potential 
for conditions such as mucositis (48, 49). In one of the registration clinical trials, VITAL, 
the efficacy and safety of isavuconazole was evaluated for treatment of a variety of 
invasive fungal diseases (IFD), including the treatment of IA in patients with renal 
impairment and treatment of patients with diseases caused by emerging moulds, yeasts, 
and dimorphic fungi. 
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In vitro data for isavuconazole have demonstrated broad-spectrum activity against a 
variety of fungi, including Aspergillus spp., Candida spp., Mucorales, Cryptococcus spp., 
and dimorphic and other rare fungi (50). Concentration-dependent antifungal activity has 
been demonstrated for infections caused by Aspergillus spp., Candida spp., organisms of 
the Mucorales order, and Cryptococcus spp. (15, 51-54). Isavuconazole demonstrated 
successful outcomes for patients with IA and IM, with all-cause mortality rates through 
day 42 of 12.5% and 37.8%, respectively, for these patients. Successful outcomes have 
also been reported for patients with IA and renal impairment, and for patients with 
infections caused by Cryptococcus spp., dimorphic fungi (such as Coccidioides spp., and 
Paracoccidioides spp.), Fusarium spp., and Scedosporium spp. (49, 55-59). The 
pharmacokinetics of isavuconazole in these various populations require further 
characterization to ensure appropriate exposures across different infections, disease types, 
and specific patient characteristics, such as mucositis. 
Micafungin  
Another challenging scenario is neonatal candidiasis that represents a disease state 
with significant morbidity and mortality in premature neonates and infants (60-62).  The 
associated mortality with invasive candidiasis (IC) is three-times higher than that of 
uninfected infants of similar gestational age and birth weight (63).  The disease is 
characterized by involvement of the central nervous system (CNS), leading to poor 
subsequent neurodevelopmental outcomes. The specific disease features dictate 
scrupulous evaluation in the selection of safe and effective antifungal regimens (64-66). 
Micafungin plays a significant role in the treatment of IC in both adults and children 
based on extensive efficacy and safety database (67). It has broad-spectrum anti-Candida 
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coverage and a favorable safety profile (68, 69). To establish the efficacious exposure of 
micafungin in CNS infections caused by Candida spp., micafungin was studied in a well-
characterized experimental model of hematogenous Candida meningoencephalitis 
(HCME) (70). PK-PD bridging studies suggest that a neonatal regimen of 10 mg/kg is 
required for effective treatment of Candida infections in the CNS (70-72). These studies 
were used to justify the choice of this high dose regimen for treatment of neonates with 
IC.  Because of the intrinsic difficulties in conducting neonatal trials and the decrease in 
the incidence of neonatal candidiasis, large-scale clinical trials are not feasible. For 
micafungin, there then lacks a good assessment of the exposure-response relationship in 
patients with higher doses of micafungin in this setting. 
VL-2397  
Early population PK models are an important step in the assessment of new 
compounds. Human phase 1 PK and safety clinical trials have recently begun and there is 
an opportunity to construct a population PK model to characterize the PK for future and 
for selection of dosage regimens for the next phase of clinical trials. VL-2397 is a natural 
product isolated from Acremonium persicinum, MF-34733. It exhibits potent fungicidal 
activity in vitro and in vivo against medically important Aspergillus species (73, 74). The 
intracellular target that is ultimately responsible for antifungal activity is not known (74, 
75). The drug is transported into the cell via a siderophore transporter, Sit1. Mammalian 
cells do not utilize the Sit1 siderophore transporter, which is one potential explanation for 
differential activity in fungi and animals. 
VL-2397 demonstrates rapid and potent in vitro fungicidal activity against 
Aspergillus fumigatus (including triazole-resistant A. fumigatus), A. terreus, A. flavus, A. 
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nidulans, Candida glabrata, C. kefyr, Cryptococcus neoformans, and Trichosporon 
asahii. Limited in vitro activity was demonstrated against Fusarium solani and does not 
appear to be active against A. niger, Candida spp. (with the exception of C. glabrata), 
Mucorales, Scedosporium apiospermum and Fonsecaea pedrosoi. Live cell imaging 
shows that VL-2397 stops hyphal elongation from germinated conidia (75). In vivo, VL-
2397 demonstrated dose-dependent prolongation of survival and reduced fungal burden 
in the lung of immunocompromised mice with invasive pulmonary A. fumigatus (76). 
VL-2397 represents an exciting new alterative in the anti-Aspergillus armamentarium. 
Aims  
This thesis was prepared to address the following aims: 
Aim 1. To utilize a well-established experimental rabbit model of invasive pulmonary 
aspergillosis (IPA) using serum galactomannan (GM) concentrations as the primary 
model readout to characterize the PK-PD relationships of isavuconazole against A. 
fumigatus. To validate the readout of the experimental PK-PD model with the clinical 
findings from the recent phase 3 clinical trial.  To define the decrement in GM in the 
rabbit that is associated with clinically relevant exposure of isavuconazole and for which 
clinical efficacy has been established. To reflect on the PD basis for establishing an in 
vitro susceptibility interpretive breakpoint of isavuconazole against A. fumigatus. 
(Chapter 3) 
Aim 2. To identify an early pattern of GM index (GMI) change that could guide 
therapeutic decision making for patients increasing the likelihood of survival and 
successful outcome by analyzing serial GMI from patients treated in a randomized, 
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double-blind trial (SECURE) in the treatment of IA or other filamentous fungi. To 
evaluate the PK-PD relationship in a subset of isavuconazole-treated patients that had 
available isavuconazole plasma concentrations and serial GMI with a goal to identify a 
drug-exposure target that can be used for individual patients. (Chapter 4) 
Aim 3. To compare PK characteristics of isavuconazole in a population of patients 
infected with a variety of fungal pathogens by constructing a PPK model for patients 
enrolled in the phase 3 VITAL trial, with the goal of comparing PK across the different 
patient populations to further understand the optimal use of isavuconazole. (Chapter 5) 
Aim 4. To examine the impact of mucositis on the bioavailability and drug exposure 
following the administration of oral isavuconazonium sulfate by constructing a 
population pharmacokinetic model using the plasma concentrations from patients 
receiving oral isavuconazole in patients with and without mucositis. To use this model to 
examine bioavailability and the ultimate drug exposure.  To consider the potential impact 
for dosing and therapeutic drug monitoring of isavuconazole in the setting of mucositis. 
(Chapter 6) 
Aim 5.To establish preclinical-to-clinical linkages based on predictions from 
preclinical models in order to prospectively validate the PK-PD relationships. To 
examined whether reaching the PD target established in preclinical models matters by 
combining micafungin plasma concentrations from 4 neonatal clinical trials to construct a 
population pharmacokinetic (PPK) model and then exploring whether increasing 
micafungin drug exposures resulted in improved clinical outcomes in infants with IC. 
(Chapter 7) 
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Aim 6. To evaluate the pharmacokinetics of a novel antifungal compound, VL-2397, 
by constructing a population PK model using plasma concentration data from phase 1 
healthy volunteer studies. (Chapter 8) 
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Chapter 2 Experimental Methods  
 
Each chapter includes detailed descriptions of the materials and methods used for the 
analyses. In this chapter, additional details to describe the over-arching methods are 
included. In order to not duplicate information in both places, items too specific to 
generalize are not repeated in this chapter (e.g. in vivo model methods in Chapter 3). 
Population PK Modeling. For each population pharmacokinetic (PPK) model, the 
non-parametric estimation in PmetricsTM (versions 1.3.2-1.5.1, University of Southern 
CA, Los Angeles, CA, USA) was utilized (77) and fitted to the plasma concentration data 
(rabbit or patient). The model fitting process included evaluating multiple compartment 
models with and without lag-time and oral bioavailability terms for compounds 
administered orally. This process was guided by visual inspection of the plasma 
concentration-versus-time curves from the observed data. The PPK models established in 
Chapters 7 and 8 utilized allometric scaling and non-linear techniques, respectively. 
The weighting functions were estimated using several different scenarios. Primarily, 
data were weighted by the inverse of the estimated assay variance from the bioanalytical 
assay calibration curve. However, in some cases, the weighting was estimated using 
ADAPT 5 (https://bmsr.usc.edu/software/adapt/ Biomedical Simulations Resource, Los 
Angeles, CA, USA) or Pmetrics error estimation runs. Specifically, in ADAPT 5, slope 
and intercept values were estimated using maximum likelihood estimation for each 
individual. The error estimation run script (i.e. ERRrun) in Pmetrics also allowed for the 
estimation of the assay error polynomial coefficients directly from the PK data. 
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In Chapters 3 and 4, linked PK-PD mathematical modeling was performed. In the 
case of Chapter 3, rabbit plasma concentrations for PK and GMI for PD were modeled 
simultaneously. In Chapter 4, modeling proceeded in a stepwise fashion because a stable 
solution could not be obtained when the PK and PD were co-modeled. Therefore, after 
fitting a model to the PK data, the posterior estimates for each patient were fixed in the 
data file for each patient so that a solution for the GM could be estimated but still allow 
for the linked model. 
Calculation of area under the concentration-time curve (AUC). The Bayesian 
posterior estimates for each individual’s PK were used to calculate the area under the 
concentration-time curve (AUC) for each individual. Depending on the study, AUCs 
were calculated at a certain time point in the dosing interval or the average AUC was 
calculated. Average AUCs were estimated by dividing the AUC for the entire dosing 
duration by the total number of days on therapy. In addition, average daily (24 hour) 
AUCs (AUCave) were calculated in Pmetrics by simulating the concentration-time profile 
for the entire dosing period and dividing by the days on therapy. 
Model Acceptance Criteria. Acceptance of the final PK and PK-PD models were 
evaluated by visual inspection of the observed versus predicted values plotted over time 
after the Bayesian step and the coefficient of determination (r2) from the linear regression 
of the observed versus predicted values. Evaluation included inspection of both median 
and mean posterior predictions. The estimated bias (mean weighted error) and 
imprecision (adjusted mean weighted squared error) were also considered. 
 46 
Monte-Carlo Simulations. Mean Bayesian parameter estimates from the fitted model 
were used to perform Monte Carlo simulations of 1000-5000 patients using Pmetrics. The 
simulations were used to calculate steady state AUCs within Pmetrics by the trapezoidal 
rule for each simulated patient. In Chapter 3, the simulations were used to bridge from 
the rabbit exposure-response data to the humans. In Chapters 4 and 5, the simulations 
were used to perform PK-PD assessments via inhibitory sigmoid Emax model and 
probability of target attainment analyses, respectively. 
Covariate Assessments. In the population PK modeling process, covariates (intrinsic 
and extrinsic) were assessed to determine the potential influence on PK parameters. This 
was accomplished by plotting the continuous covariate against the individual estimates 
for clearance and volume. Significance was determined after linear regression of the data. 
If the 95% confidence interval for the slope did not include zero, the impact of the 
covariate was deemed significant. In the case of Chapter 6, mucositis was evaluated 
directly after a difference was seen from initial assessment of the observed plasma 
concentrations in patients with mucositis compared to those without. 
Statistical Analyses. Statistical comparisons were performed in MYSTAT 12 (version 
12.02; Systat Software, Inc.; http://www.systat.com) and GraphPad Prism versions 6.0h 
and 7.0h (http://www.graphpad.com). In Chapter 4, the statistical approach was 
performed in R and described in detail in that chapter. In Chapter 5, the exposure-
response analysis was performed by logistic regression in SAS® (version 9.3, SAS 
Institute Inc., Cary, NC, USA).  
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Chapter 3 Pharmacodynamics of isavuconazole in experimental invasive 
pulmonary aspergillosis. Implications for clinical breakpoints 
 
Abstract 
Objectives. Isavuconazole, a novel triazole antifungal agent, has broad-spectrum 
activity against Aspergillus spp. and other pathogenic fungi. Isavuconazole exposure-
response relationship in experimental invasive pulmonary aspergillosis using 
galactomannan index (GMI) suppression as a marker of disease clearance was explored.  
Methods. The impact of exposure on GMI suppression in persistently neutropenic 
rabbits treated with isavuconazonium sulfate (isavuconazole-equivalent dosages of 20, 
40, or 60 mg/kg q24h, after a 90 mg/kg loading dose) for 12 days was linked using 
mathematical modeling. Bridging to humans using population pharmacokinetic (PK) data 
from a clinical trial in invasive aspergillosis was performed using Monte Carlo 
simulations.  
Results. Mean plasma isavuconazole area under the concentration-time curve over 
MIC (AUC/MIC) (EC50) of 79.65 [95% CI 32.2, 127.1] produced a half maximal effect 
in GMI suppression. The inhibitory sigmoid Emax curve dropped sharply after an 
AUC/MIC of ≥30 and was near maximum (EC80) at approximately 130. Bridging the 
experimental pharmacokinetic-pharmacodynamic (PK-PD) target to human population 
PK data was then used to return to the rabbit model to determine a clinically relevant PD 
endpoint. The clinical dosing regimen used in the trial would result in a mean GMI of 4.3 
(±1.8), which is a 50% reduction from the starting GMI in the experiment.  
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Conclusion. The clinical trial data results showing the non-inferiority of 
isavuconazole to voriconazole further support the PK-PD endpoint, thereby 
demonstrating the usefulness of the rabbit model and its endpoint for isavuconazole and 
has implications on interpretive breakpoints. Importantly, the analysis supports this 
model as an important tool for development of antifungal agents.  
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Introduction  
Isavuconazole is a novel broad-spectrum triazole antifungal agent, which is available 
as the prodrug, isavuconazonium sulfate, in both intravenous and oral formulations, and 
which was recently approved by the US Food and Drug Administration for the primary 
treatment of invasive aspergillosis (IA) and mucormycosis in adults (78). IA is a life-
threatening disease that causes significant morbidity and mortality in patients who are 
severely immunocompromised.(5, 6) Isavuconazole is the first agent that has been 
developed for IA for 12 years. Despite the recent demonstration of non-inferiority of 
isavuconazole compared with voriconazole, there is relatively little information regarding 
exposure-response relationships of isavuconazole against Aspergillus spp. that are 
required for a complete understanding of the clinical utility of this agent. 
Laboratory animal models that mimic human disease have long been used to 
characterize pharmacological efficacy and safety prior to clinical use. Importantly, well-
designed animal models used in antimicrobial development are generally highly 
predictive of clinical efficacy (79). Over the past 20–30 years these experimental models 
have enabled an exploration of the relationship between the time-course of drug 
exposure, penetration of drug to the site of infection and the ultimate antimicrobial effect 
(1). The treatment of infections caused by Aspergillus spp. and rare filamentous fungi is 
relatively difficult to study in clinical settings. A detailed understanding of exposure-
response relationships underpins the design of antifungal regimens that are safe and 
effective and enables the right dose to be studied the first time. An understanding of 
antifungal pharmacokinetic (PK)-pharmacodynamic (PD) properties also provides the 
foundation for treatment and prevention of antimicrobial resistance, determination of the 
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requirement for therapeutic drug monitoring, and decision support for establishing in 
vitro susceptibility breakpoints. 
Here, we describe the use of a well-established experimental rabbit model of invasive 
pulmonary aspergillosis (IPA) using serum galactomannan (GM) concentrations as the 
primary model readout to characterize the PK-PD relationships of isavuconazole against 
A. fumigatus. We were in a unique position of being able to validate the readout of the 
experimental PK-PD model with the clinical findings from the recent phase 3 clinical 
trial.  We defined the decrement in GM in the rabbit that is associated with clinically 
relevant exposure of isavuconazole and for which clinical efficacy has been established. 
We then reflected on the PD basis for establishing an in vitro susceptibility interpretive 
breakpoint of isavuconazole against A. fumigatus. 
Methods and Materials  
Rabbit model of invasive pulmonary aspergillosis. A previously described 
persistently neutropenic rabbit model of IPA was used (15, 80). Healthy female New 
Zealand white rabbits (Covance Research Products, Inc., Denver, PA, USA) weighing 2.6 
to 3.5 kg were used in the study. Immunosuppression and profound persistent neutropenia 
(neutrophil concentration of <100 neutrophils/µL) was established by administration of 
cytarabine (Ara-C) (Cytarabine injection; Zydus Hospira Oncology Private Ltd, Gujarat, 
India for Hospira, Inc., Lake Forest, IL, USA) at an initial dose of 525 mg/m2 for 5 
consecutive days beginning on day 1 of the experiment and a maintenance dose of 484 
mg/m2 on days 8, 9, 12 and 13 of the experiment. Methylprednisolone (Solu-Medrol®, 
Pfizer for Pharmacia & Upjohn Co., Division of Pfizer Inc., New York, NY) was dosed at 
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5 mg/kg on days 1 and 2 (80). Bacterial infection prophylaxis was maintained with 
antibiotics (ceftazidime, gentamicin, vancomycin) as previously described (80). 
Ethics. Rabbits were monitored under humane care and use of standards in facilities, 
accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care International, and according to the guidelines of the National Research Council for 
the care and use of laboratory animals, and under the approval of the Animal Care and 
Use Committee of Weill Cornell Medical Center, New York, NY, USA. Rabbits were 
housed individually and fed ad libitum.  
Organism and MIC. NIH 4215 (ATCC No. MYA-1163), which is a well-
characterized clinical isolate of A. fumigatus, was used for all experiments (80). The 
MICs of voriconazole and isavuconazole against A. fumigatus determined using Clinical 
and Laboratory Standards Institute (CLSI) standard M38-A2 broth microdilution 
methodology were 0.5 mg/L and 1 mg/L, respectively (81). The MICs were measured in 
triplicate. 
Treatment. Rabbits received either prodrug, isavuconazonium sulfate, at an 
isavuconazole (BAL4815; active moiety) equivalent dose of 20 (ISAV20), 40 (ISAV40), 
and 60 (ISAV60) mg/kg/day or were untreated controls. A loading dose of the prodrug 
equivalent to isavuconazole 90 mg/kg was given on the first day of antifungal treatment 
to all isavuconazole-treated rabbits. Treatment was initiated 24 h after inoculation and 
administered orally once daily thereafter for up to 12 days. Multiple outcome variables 
were analyzed from the model including survival, pulmonary infarct score, lung weight, 
residual fungal burden (log cfu/g), serum galactomannan index (GMI), bronchoalveolar 
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lavage (BAL) fluid GMI, and serum (13)--D glucan levels, as previously described 
(15). 
Herein, we report the results of the isavuconazole-treated animals with a particular 
focus on the serum GM experiments and PK-PD mathematical modeling, with a brief 
description of the primary efficacy results. The primary efficacy results from the animal 
model are published elsewhere (15). 
Pharmacodynamic assessment. Blood was collected via the indwelling Silastic 
catheter at 24 h post-inoculation, just prior to initiation of antifungal treatment and every 
other day thereafter for determination of the serum GM concentrations. Concentrations 
were determined by one-stage immunoenzymatic sandwich microplate assay method (the 
Platelia® Aspergillus Enzyme Immunoassay (EIA) (Bio-Rad, Marnes la Coquette, France) 
(13), and according to the manufacturer’s instructions. 
Pharmacokinetics. Single-dose PK analyses were conducted in four non-infected 
rabbits in each dosage group. Time points included pre-dose, 1, 2, 4, 8, 12, 18, 24, and 48 
h post-dosing. Multiple-dose PKs were determined in infected animals 7 days post-
inoculation. Blood samples were drawn pre-dose and at 1, 4, 8, and 24 h post-dosing. 
Each blood sample for PK assay was collected in heparinized syringes. Plasma samples 
were immediately separated by centrifugation at 400 g and stored at -80°C until assayed.  
Measurement. Isavuconazole was measured using liquid chromatography/mass 
spectrometry/mass spectrometry (LC/MS/MS). Samples were prepared by adding 0.1 M 
paraoxon (10 μL per 1 mL of plasma) to the blank EDTA/K3 and blank Li-heparin rabbit 
plasma in order to inhibit esterases. Spiking solutions were prepared by serial dilution in 
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dimethyl sulfoxide (DMSO) and acetonitrile (ACN), 0.05% trifluoracetate (TFA) out of a 
2 mg/mL stock solution with a range from 0.5 μg/mL to 500 μg/mL. Calibration samples 
were performed by spiking 1 μL of each DMSO (or ACN, 0.05% TFA) solution in 99 μL 
of blank EDTA/K3 plasma. Each sample was then quenched with 300 μL of ACN, 0.05% 
TFA containing 1 μg/mL of BAL0004815-d4, and pyridooxazinone as internal standards. 
After centrifugation, 10 μL of the supernatant was injected into the LC/MS/MS. A 
similar preparation method was performed for the QC samples; however, blank Li-
heparin plasma was used instead of the EDTA/K3 plasma. For the samples, 50 μL of 
plasma was mixed with 150 μL of ACN, 0.05% TFA containing 1 μg/mL of 
BAL0004815-d4, and pyridooxazinone as internal standards, then treated like the 
calibrators. Assay linear range was 0.005 to 4.45 μg/mL and coefficient of variation 
(%CV) ranged from 1.1 to 10.7%. The lower limit of quantification of the plasma assay 
was 0.005 μg/mL. 
Pharmacokinetic and pharmacodynamic mathematical modeling. Mathematical 
modeling was performed in a step-wise manner. First, a population pharmacokinetic 
(PPK) model was constructed using non-parametric estimation in PmetricsTM software 
(v1.3.2, University of Southern CA, Los Angeles, CA, USA)(77) and fitted to the rabbit 
plasma concentration data. The weighting functions were estimated using a combination 
of ADAPT 5 (https://bmsr.usc.edu/software/adapt/ Biomedical Simulations Resource, 
Los Angeles, CA, USA) and Pmetrics error estimation runs. Specifically, in ADAPT 5, 
slope and intercept values were estimated using maximum likelihood estimation for each 
individual rabbit. In Pmetrics, the error estimation run script (i.e. ERRrun) was used to 
estimate the assay error polynomial coefficients directly from the data. After establishing 
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a model that best described the PK data, the GM concentrations were added to the dataset 
for each individual rabbit. A linked PK-PD model was built using the following set of 
differential equations: 
Equation 1  
 
𝑑𝑋(1)
𝑑𝑡
= −𝐾𝑎 ∙ 𝑋(1) 
Equation 2  
𝑑𝑋(2)
𝑑𝑡
=  𝐾𝑎 ∙ 𝑋(1) − ((
𝐶𝑙
𝑉
) ∙ 𝑋(2)) − 𝐾𝑐𝑝 ∙ 𝑋(2) + 𝐾𝑝𝑐 ∙ 𝑋(3)  
Equation 3  
 
𝑑𝑋(3)
𝑑𝑡
=  𝐾𝑐𝑝 ∙ 𝑋(2) − 𝐾𝑝𝑐 ∙ 𝑋(3) 
Equation 4  
 
𝑑𝑋(4)
𝑑𝑡
=  𝐾𝑝𝑚𝑎𝑥 ∙ (1 − (
(
𝑋(2)
𝑉
)
𝐻𝑝
𝐶50𝑝𝐻𝑝+(
𝑋(2)
𝑉
)
𝐻𝑝)) ∙ 𝑋(4) ∙  
(1 − (
𝑋(4)
𝑝𝑜𝑝𝑚𝑎𝑥
)) − 𝑘𝑠𝑚𝑎𝑥 ∙ 𝑋(4) ∙ (
(
𝑋(2)
𝑉
)
𝐻𝑠
𝐶50𝑠𝐻𝑠+(
𝑋(2)
𝑉
)
𝐻𝑠)  
The first three equations describe the pharmacokinetics of the drug, (compartment 1, 
theoretical absorptive compartment for oral administration; 2, central compartment, and 
3, peripheral compartment). Cl is the clearance defined, as the amount of drug being 
cleared from the central compartment over time and V is the volume of the central 
compartment. Ka is the first order absorption constant, Kcp is the rate of drug moving 
from the central to peripheral compartment and Kpc is the rate of drug moving from the 
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peripheral to central compartment. Equation 4 describes the rate of change of the serum 
GM values. Kpmax represents the maximum rate of production, Hp is the slope function 
for production, C50p is the amount of drug where there is half maximal production, 
popmax is the theoretical maximum density of GM, ksmax is the maximum rate of GM 
suppression, C50s is the amount of drug where there is half maximal suppression, and Hs 
is the slope function for the GM suppression.   
Acceptance of the final model was evaluated by visual inspection of the observed 
versus predicted values plotted over time after the Bayesian step, the coefficient of 
determination (r2) from the linear regression of the observed versus predicted values, as 
well as, evaluation of the estimated bias and imprecision. After fitting the model to the 
PK-PD data, the Bayesian posterior estimates for each rabbit were used to estimate the 
concentration-time profiles for isavuconazole and GMI for each rabbit. Simulations were 
performed in ADAPT 5. Area under the plasma concentration-time curves (AUCs) were 
calculated by integration from the simulated concentration-time profiles on the last day of 
dosing (at steady-state) in ADAPT 5.  
Using the simulated isavuconazole AUC values and the GMI at the end of the dosing 
period for each rabbit, an inhibitory sigmoid Emax model was constructed to establish the 
pharmacodynamic relationship between exposure (AUC) divided by MIC and response 
(GMI). The model used is described below: 
Equation 5  
𝑬𝒇𝒇𝒆𝒄𝒕 = 𝑬𝟎 − (
𝑬𝒎𝒂𝒙∙(
𝑨𝑼𝑪
𝑴𝑰𝑪
)
𝑯
𝑬𝑪𝟓𝟎𝑯+(
𝑨𝑼𝑪
𝑴𝑰𝑪
)
𝑯)  
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E0 is the baseline level of GM prior to exposure to drug, Emax is the maximum GM 
value, EC50 is a measure of drug potency, and H is the slope factor. 
Bridging to humans. To bridge the exposure-response results from the rabbits to 
humans, a PPK model was constructed using the isavuconazole plasma concentration 
data from the phase 3 SECURE clinical trial (48). The SECURE (NCT00412893) trial 
evaluated the efficacy and safety of isavuconazole compared to voriconazole in the 
treatment of patients with possible, probable or proven IA and other filamentous fungi. 
Patients that were randomized to isavuconazole received the prodrug, isavuconazonium 
sulfate, at a dose of 372 mg every 8 h for the first 2 days followed by 372 mg once daily 
thereafter (equivalent to isavuconazole at a dose of 200 mg (IV) q8h for 2 days, then 200 
mg once daily). The option to receive either IV or oral was allowed after day 2. The 
maximum treatment duration was 84 days. Plasma trough samples were collected on days 
7, 14, 42, end of treatment and follow-up for some patients. Serial plasma samples (seven 
in total) from less than 25 subjects were collected on day 7 (± 1 day) or 14 (+ 1 day) for 
PK profiling. Overall, 113 patients with isavuconazole concentrations were used for the 
analysis.  
A PPK model using non-parametric estimation was developed in Pmetrics™ (v1.3.2, 
University of Southern California, CA, USA) (77). The model fitting process included 
evaluating both two- and three-compartment models with and without lag-time and oral 
bioavailability terms.  
Mean Bayesian parameter estimates from the fitted human model were used to 
perform Monte Carlo simulations of 1000 patients using Pmetrics. The simulations were 
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used to calculate steady state AUCs within Pmetrics by the trapezoidal rule for each 
simulated patient. Using equation 5 above, the effect of AUC:MIC at various MIC values 
representative of the MIC distribution of isavuconazole for A. fumigatus as described by 
Espinel-Ingroff et al. was calculated (82). Total isavuconazole drug levels are used 
wherever isavuconazole concentration or AUCs are reported unless otherwise specified. 
Results  
Animal model. Significant reduction of residual fungal burden, lung weights, and 
pulmonary infarct score was demonstrated in the two highest dosage groups of ISAV40 
and ISAV60 compared with untreated controls (P<0.001, ANOVA with Bonferroni’s 
correction for multiple comparisons). The highest dose of isavuconazole significantly 
prolonged survival compared to untreated controls (P<0.001, log-rank test). The lowest 
dosage of ISAV20 also significantly prolonged survival versus untreated controls 
(P<0.05, log-rank test) (15).  
Dose-dependent reductions in biomarkers were demonstrated for isavuconazole-
treated animals. ISAV40 and ISAV60 dosage groups significantly decreased the GMI 
during therapy following day 4 compared to increased GMI in the untreated controls 
(P<0.01). Figure 1 illustrates GMI versus time for the rabbits treated with 
isavuconazonium.   
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Figure 1 Galactomannan index (GMI) versus time for each rabbit after 
administration of isavuconazonium sulfate (all dose groups) Individual lines represent 
the GMI values over time for each rabbit. The colors clarify the dosage for each rabbit. 
 
 
BAL GMI was also significantly reduced in ISAV40 and ISAV60 dosage groups 
versus untreated controls (P<0.001, ANOVA with Bonferroni’s correction for multiple 
comparisons). Serum (13)-β-D-glucan levels were significantly reduced in ISAV40 
and ISAV60 compared to untreated controls (P<0.05, ANOVA with Bonferroni’s 
correction for multiple comparisons) (15). 
PK-PD modeling. Visual inspection of the raw concentration-time profile of the three 
isavuconazole dosages suggested linear isavuconazole pharmacokinetics in the rabbit. A 
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two-compartment model with first-order absorption fit the rabbit plasma isavuconazole 
drug concentration data well. The fit of the linked PK-PD model was also acceptable 
based on a coefficient of determination for the observed versus predictive values after the 
Bayesian step of 0.965 and 0.895 for the PK concentrations and GMI, respectively 
(Figure 2).  
Figure 2 Regression plot of observed (y-axis) versus model predicted (x-axis) 
plots from rabbit isavuconazole population PK (A) and galactomannan index (GMI) 
(B). Logistic regression of observed versus predicted concentrations. In both figures, the 
solid line represents the slope of the correlation and the circles and squares are the 
individual concentrations (values) for plasma (A) and GMI (B), respectively. The 
coefficient of determination for the observed versus predictive values after the Bayesian 
step of 0.965 and 0.895 for the PK concentrations (A) and GMI (B), respectively. 
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The estimates of bias and imprecision for the rabbit PK were -0.14 and 1.05, and        
-0.288 and 0.892 for GMI, respectively. Parameter estimates from the final model are 
summarized in Table 2. 
Table 2 Mean and standard deviations (SD) values for each parameter estimated 
from the rabbit population PK-PD linked model  
Parameter (units) Mean SD 
Ka (h-1) 20.145 8.842 
Cl/F (L/h) 1.108 1.228 
V/F (L) 27.911 6.872 
Kcp (h-1) 5.953 2.498 
Kpc (h-1) 6.394 2.916 
Kpmax (GMI/h) 0.115 0.047 
Hp 17.220 4.116 
C50p (mg/L) 1.286 1.548 
IC (GMI) 0.108 0.053 
Ksmax (GMI/h) 0.009 0.002 
Hs 12.292 5.029 
C50s (mg/L) 0.167 0.127 
Popmax (GMI) 6.642 2.324 
Abbreviations: SD, standard deviation; Ka, first-order rate constant describing the movement of drug from the gut to 
the central compartment; Cl, clearance from the central compartment; V, volume of the central compartment; F, 
bioavailability; Kcp, rate of drug moving from central to peripheral compartment; Kpc, rate of drug moving from 
peripheral to central compartment; Kpmax, maximum rate of GM production, Hp, slope function for production; C50p, 
amount of drug where there is half maximal production; IC, initial condition of GMI prior to drug exposure; Ksmax, 
maximum rate of GMI suppression; Hs, slope function for GMI suppression; C50s, amount of drug where there is half 
maximal suppression; Popmax, theoretical maximum density of GMI. 
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The exposure-response relationship showed that the GMI responded sharply for 
AUC:MIC of ≥30 (Figure 3). The AUC:MIC that induced the half-maximal effect (EC50) 
was estimated at 79.65 [95% CI 32.2, 127.1], which resulted in a 50% reduction in GMI. 
Suppression of GMI was a near maximum (EC80) at an AUC:MIC of approximately 130.  
Figure 3 Inhibitory sigmoid Emax curve demonstrating the exposure-response 
relationship of isavuconazole exposure in terms of the plasma AUC:MIC (x-axis) 
and the associated terminal GM) value (y-axis). The black squares represent the 
observed GMI value for each rabbit (+/- SEM). The continuous black line represents the 
fit of the inhibitory sigmoid Emax model to the data. 
 
Bridging to humans. Human isavuconazole plasma drug concentrations from the 
phase 3 SECURE clinical trial in patients with IA or other filamentous fungi were used to 
𝐸𝑓𝑓𝑒𝑐𝑡 = 8.19 − (
8.17 (
𝐴𝑈𝐶
𝑀𝐼𝐶 )
2.77
79.652.77 + (
𝐴𝑈𝐶
𝑀𝐼𝐶 )
2.77) 
r2 = 0.648 
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construct a non-parametric PPK model using Pmetrics software (77). A two-compartment 
model with first order absorption fit the data well with a coefficient of determination after 
the Bayesian step of 0.877. Visual inspection of the observed versus predicted values was 
acceptable, as well as, measures of bias and imprecision. The mean parameter estimates 
from the PPK model for the P3 human plasma concentrations are presented in Table 3. 
Table 3 Mean and standard deviation (SD) values for each parameter estimated 
from the human population PK model  
Parameter (units) Mean SD 
Ka (h-1) 24.3 16.7 
Cl/F (L/h) 2.2 1.1 
V/F (L) 398.8 225.2 
F (%) 90.2% 20.9% 
Tlag (h) 1.5 3.3 
SD, standard deviation; PK,  Ka, first-order rate constant that describes the movement of drug from the gut to the 
central compartment (h-1); Cl, clearance (L/h); V, volume of distribution (L); F, bioavailability; Tlag, lag time (h). 
Monte Carlo simulations using the mean parameter estimates from the human PPK 
model were performed. The AUCs for 1000 simulated patients were estimated using the 
linear trapezoidal rule in the “makeAUC” function within Pmetrics.  The mean steady-
state AUC  SD for the simulated population was 82.6  33.0 mg h/L.  The 
corresponding drop in GMI in rabbits receiving human-like exposures of isavuconazole 
was 4.3  1.8, which closely approximates the EC50 for GMI reduction (4.1 GMI units) 
from the start of the experiment in the rabbits (E0=8.2). 
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After Monte Carlo simulations of 1000 patients, the effect of AUC:MIC at different 
MIC values relevant to the wild-type (WT) MIC distribution of A. fumigatus for 
isavuconazole as tested by CLSI methodology is displayed in Figure 4. The figure 
illustrates the predicted GMI at the end of the experiment given the inherent PK 
variability in humans as a function of each MIC value following the administration of the 
regimen of isavuconazonium sulfate that was used in the recent clinical trial. 
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Figure 4 Frequency distribution of terminal galactomannan values at each MIC 
value. Monte Carlo simulation of 1000 subjects after exposure to the clinical dosing 
regimen of isavuconazonium sulfate. The colored bars represent the frequency of each 
GMI value for an organism at that MIC value after treatment with the standard clinical 
dosage regimen of isavuconazonium sulfate (372 mg every 8 hours for 2 days, followed 
by 372 mg once daily thereafter). 
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Discussion  
Isavuconazole is a novel triazole antifungal agent that is administered as the water-
soluble prodrug isavuconazonium sulfate. This novel agent demonstrated non-inferior 
efficacy (as defined by upper bound of the 95% CI less than the pre-specified 10% non-
inferiority margin) compared with voriconazole for all-cause mortality up to day 42 
(18.6% versus 20.2%, intent-to-treat population) in the SECURE trial for the treatment of 
IA and invasive disease caused by other filamentous fungi. 
The clinical trial results enable a retrospective validation of the clinical validity of the 
endpoints used in the experimental PK-PD model. An isavuconazole AUC that has been 
associated with clinical efficacy that is at least as good as the current standard of care (i.e. 
voriconazole) induces a 50% reduction in circulating GM concentrations in the 
persistently neutropenic rabbit model of IPA. Thus, the rabbit model as currently 
designed produces an “on scale” readout that appears clinically relevant and tractable. 
These analyses provide a unique opportunity to evaluate the predictive nature of the 
rabbit model endpoints and further facilitate the use of this model for the future 
development of new antifungal agents.  
The findings in this study also have implications for setting in vitro susceptibility 
breakpoints for isavuconazole against A. fumigatus. The recent clinical study (SECURE) 
clearly suggests that isavuconazole is an effective agent for the treatment of IA. If an 
assumption is made that the vast majority of isolates in the clinical trial are WT 
organisms then A. fumigatus is considered to be a “good target” for isavuconazole. In the 
absence of other clinical or PD data, the breakpoint for isavuconazole against A. 
fumigatus is ordinarily set at the epidemiological cut-off value (ECV or ECOFF), which 
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is ≤1 mg/L (82). There is no evidence from the SECURE study that there is a relationship 
between MIC and clinical outcome; although the number of patients with a positive 
culture was too small to enable a definitive analysis. This pharmacodynamic study 
provides further perspective on the validity of using 1 mg/L as a breakpoint. Without 
making any assumptions about a GMI cut-off value that defines therapeutic success and 
failure, Figure 3 shows the predicted GMI values for patients receiving a standard 
clinical isavuconazole regimen and infected with isolates with a range of MICs. The 
histograms in Figure 4 suggest that a ≥ 50% reduction in GMI is achieved for 
isavuconazole MICs <1 mg/L. Similarly, GM antigen expression is not suppressed in 
patients with an MIC ≥2 mg/L. For an MIC of 1 mg/L some patients have suppressed 
GM antigen expression while others do not. Therefore, an MIC of 1 mg/L may on 
occasions be difficult to treat and be therefore classified as intermediate to denote the fact 
that isavuconazole should be used with some caution in this situation. 
The PK-PD relationship for isavuconazole against Aspergillus spp. has been 
described for a variety of other experimental designs; however, given the results of the 
clinical trial, not all appear to predict the clinical response for isavuconazole well. 
Therefore, it is important to understand the key differences between the models and how 
those differences may have an impact on the development of a new antifungal drug. 
Lepak et al. used a neutropenic murine model of IPA (51). The model used a diverse 
group of organisms (10 in total) ranging from WT organisms to organisms with well-
characterized cyp51a point mutations. In contrast to the current model, primary efficacy 
was defined by the net stasis in fungal growth as measured by the density of fungal DNA 
in the lung. The estimated total drug PD target (AUC:MICclsi) from this experiment was 
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503. In contrast, Seyedmousavi et al. evaluated isavuconazole in a non-neutropenic 
mouse model of disseminated aspergillosis (83). Similar to the model of Lepak et al, this 
model utilized both WT and cyp51a mutants. However, the primary outcome measure 
was 14-day survival. The total drug AUC:MICclsi target associated with 50% survival 
(EC50) was 10-fold lower and estimated to be approximately 50.  
The estimated half-life of isavuconazole in rabbits (17.5 h) is significantly longer than 
in mice (1–5 h) (51). The difference in half-life between the two animal models could 
have an impact when estimating the PD target in severe experimental conditions (e.g. 
profound and prolonged neutropenia). The relative absence of neutrophils combined with 
long periods of the dosing interval where drug concentrations are beneath a critical 
threshold may enable fungal regrowth. Progressively higher dosages of isavuconazole are 
then required to achieve concentrations that prevent fungal regrowth. It is therefore 
possible that the rapid clearance of drug, the use of dosing intervals (every 12 h) that are 
many multiples of the half-life and the severe nature of the model conspire to produce an 
inaccurate estimate of drug exposure that is ultimately required for therapeutic efficacy.   
In addition to the animal models described above, an in vitro human alveolus model 
of experimental pulmonary aspergillosis was conducted (84). The total drug AUC:MIC 
estimated for this system was 11. This lower value probably largely reflects the finding 
that the model best simulates early (first 24 hours) versus more established disease (>24 
hours) (27).  The in vitro alveolus model also does not reflect the tissue injury, including 
hemorrhagic infarctions, which may impair penetration of the antifungal agent to the 
invading hyphae. These factors are important determinants of the drug exposure required 
to suppress circulating GM antigen concentrations. 
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Limitations in the reproducibility of GM measurements have been reported. One 
report describes a meta-analysis of 27 studies where GM was used in the clinic as a 
surveillance measure for the development of IA. The analysis was done to characterize 
the performance of the test and also to determine variables that might affect the 
performance (17). The authors describe sensitivity and specificity values of 0.61 (95% CI, 
0.59–0.63) and 0.93 (95% CI, 0.92–0.94), respectively, for the combined proven and 
probable cases. The sensitivity of the test decreases for solid organ transplant patients and 
when a reference standard such as EORTC/MSG was utilized. Other studies have reported 
decreased sensitivity with prior antifungal therapy use (85). These factors are not likely to 
play a role in the findings presented in this report. Reproducibility due to technical aspects 
of the assay has also been reported. In 2015, Guigue and colleagues performed a study to 
identify operational factors that may result in the lack of reproducibility of the GM assay 
results (86). They found approximately 30% of the positive GM results were not 
reproducible. To account for this, they suggest retesting the sample and performing serial 
samples. Given the current study utilizes serial sampling of the rabbit sera, these issues are 
less likely to impact the current study. 
When one considers the possible use of these PD targets in drug development, it is 
clear that even small differences may have a significant impact on the regimen that is 
ultimately chosen and the establishment of in vitro susceptibility breakpoints. For 
example, use of the PD target defined in the neutropenic mouse model would have placed 
the isavuconazole breakpoint in the middle of the WT population (at 0.06 mg/L), which is 
neither ideal nor consistent with clinical trial findings. A corollary is that a much higher 
dose would have been predicted to be successful than was ultimately used in the clinical 
trial. The rabbit model provides “on scale readouts” for isavuconazole and a clinically 
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relevant model readout of a 50% reduction in GMI. Thus, complete suppression of GM 
antigen, which may be desirable when treating a patient with IA, is not a relevant 
consideration for PK-PD bridging studies (in the same way that 100% survival may not 
be possible or reasonable). Therefore, all the preclinical PK-PD studies for isavuconazole 
and the subsequent bridging studies provide a salutary lesson in the use of PK-PD models 
for drug development. Orthogonal reasoning should be applied, models must be stressed, 
positive controls should be used to benchmark model performance and readouts, and 
findings should be repeatedly cross-checked.  
This study has several limitations. First, only one WT organism of A. fumigatus was 
used in the experimental model. A more diverse group of organisms with a range of 
MICs including organisms with well-characterized resistance mechanisms would provide 
a more robust assessment of the exposure-response relationship. Second, the 
experimental findings as presented are only relevant to CLSI methodology. Third, a small 
number of terminal GMI values fall in the middle of the curve suggesting that the results 
could be driven by the majority of values that occur at the extremes of effect or no effect. 
Nevertheless, this study provides further evidence that GM is a robust clinically relevant 
biomarker that can be used to characterize the pharmacodynamics of anti-Aspergillus 
agents. A 50% reduction in GMI in this persistently neutropenic rabbit model of IPA 
correlates well with the results of the phase 3 clinical trial for isavuconazole which 
provided a foundation to further characterize the PD of new antifungal agents, and the 
selection of new regimens for study in early-phase clinical trials. 
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Chapter 4 Pharmacodynamics of Isavuconazole for Invasive Mould 
Disease: Role of Galactomannan for Real-Time Monitoring of 
Therapeutic Response  
 
Abstract  
Background. The ability to make early therapeutic decisions when treating invasive 
aspergillosis using changes in biomarkers as a surrogate for therapeutic response could 
significantly improve patient outcome. 
Methods. Cox proportional hazards model and logistic regression were used to 
correlate early changes in GMI to mortality and overall response, respectively, from 
patients with positive baseline GMI (≥ 0.5) and serial GMI during treatment from a phase 
3 clinical trial for the treatment of invasive mould disease. PK-PD analysis in patients 
with isavuconazole plasma concentrations was conducted to establish the exposure 
necessary for GMI negativity at the end of therapy. 
Results. The study included 158 patients overall and 78 isavuconazole patients in the 
PK-PD modeling. By Day 7, GMI increases of > 0.25 units from baseline (3/130 
survivors; 9/28 that died) significantly increased the risk of death compared to those with 
no increase or increases below 0.25 (Hazard Ratio 9.766; 95% CI 4.356, 21.9, p<0.0001). 
For each unit decrease by Day 7 from baseline, the odds of successful therapy doubled 
(Odds Ratio 2.154, 95% CI 1.173, 3.955). An AUC:EC50 of 108.6 is estimated to result in 
a negative GMI at the end of isavuconazole therapy. 
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Conclusions. Early trends in GMI are highly predictive of patient outcome. GMI 
increases by Day 7 could be considered in context of clinical signs to trigger changes in 
treatment, once validated. Our data suggests this improves survival by 10-fold and 
positive outcome by 3-fold. These data have important implications for individualized 
therapy for patients and clinical trials.  
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Introduction  
Invasive fungal diseases caused by Aspergillus spp. are a persistent public health 
problem (87-89). Therapeutic options are few and limited by toxicity, an incomplete 
spectrum of antifungal activity and acquired drug resistance (7-11). Treatment is initiated 
when tissue damage is established, usually evidenced by radiographic abnormalities.  
Assessing the response to therapy at the bedside is difficult. Clinical signs and symptoms 
are nonspecific and radiological abnormalities may paradoxically deteriorate despite 
otherwise successful therapy (89).  Thus, ways to objectively monitor the response to 
antifungal therapy and make rational therapeutic choices would significantly improve 
antifungal stewardship and potentially improve clinical outcomes. 
The widespread use of galactomannan (GM) detection and quantification has 
improved the speed and accuracy of a diagnosis of invasive aspergillosis (IA). Serum GM 
is often detectable prior to the onset of clinical signs and symptoms of infection (88, 89) 
and has been used successfully as a surrogate for therapeutic response (14, 15, 90). A 
decline in GM or GM negativity has been linked to clinical outcomes, eg, survival or 
successful clinical response, was reported to correlate in patients that do well (18-21). 
However, interpretive criteria used to direct therapeutic decision-making are lacking. 
To identify an early pattern of GM index (GMI) change that could guide therapeutic 
decision making for patients increasing the likelihood of survival and successful 
outcome, we analyzed serial GMI from patients treated in a randomized, double-blind 
trial (SECURE) in the treatment of IA or other filamentous fungi. We also analyzed a 
subset of isavuconazole-treated patients that had available isavuconazole plasma 
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concentrations and serial GMI to evaluate the PK-PD relationship with a goal to identify 
a drug-exposure target that can be used for individual patients. 
Methods  
Study Design. Patients from the SECURE trial (NCT00412893), a phase 3, 
randomized, double-blind study comparing isavuconazonium sulfate to voriconazole for 
the treatment of invasive mould disease caused by Aspergillus spp. or other filamentous 
fungi, were eligible (48). The evaluation of the use of GM as a biomarker was pre-
specified as an exploratory objective. Patients from the modified intent-to-treat (mITT; 
all patients receiving study drug with proven or probable invasive mould infections, as 
determined by an independent blinded data review committee (DRC)) population who 
had a positive baseline serum GMI (optical density (OD) ≥0.5) plus one or more post-
baseline (>day 7) GMI were included. Patients were eligible for the PK-PD analysis if 
plasma samples were collected to enable an estimate of isavuconazole plasma exposure.  
Eligibility criteria for the main trial are detailed elsewhere (48). Patients randomized 
to the isavuconazole group received the prodrug, isavuconazonium sulfate, as a loading 
regimen intravenously (i.v.) over days 1 and 2 at a dose of 372mg (equivalent to 200mg 
of isavuconazole) every 8 hours, followed by a maintenance dose of 372mg once daily, 
given either i.v. or orally (p.o.). Voriconazole patients received i.v. 6mg/kg twice daily on 
day 1 followed by 4mg/kg i.v. twice daily on day 2. From day 3 onwards, voriconazole 
was administered as an i.v. infusion (4mg/kg twice daily) or orally (200mg twice daily). 
The patients were treated for up to 84 days. 
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Outcome Measurements. The primary efficacy outcome measure was all-cause 
mortality through day 42. Secondarily, overall response at the end of therapy (EOT) as 
evaluated by the DRC was assessed. Successful overall response was defined as a 
composite of complete or partial clinical and radiological response, plus a mycological 
response of eradication or presumed eradication. The response criteria are detailed 
elsewhere (48). 
GM Measurements. Protocol-defined serum samples were drawn at screening, on 
days 1, 2, 14, 28, 42, 84, and EOT. Samples drawn on an ad hoc basis were included. In 
total, 1347 GMI values were available with 114 around day 7 (+/-1 day) (see Figure 5).  
Figure 5 Number of GMI values per day through Day 42 Each bar represents the 
frequency (number) of GM values available on each day of treatment for the population. 
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A central laboratory analyzed protocol-defined samples, while ad hoc basis were 
analyzed locally. Specimens were stored at -20°C until shipped to the central laboratory 
(Eurofins Global Central Laboratory, Chantilly, VA) and assayed using Platelia 
Aspergillus enzyme immunoassay (EIA) from Bio-Rad Laboratory according to the 
manufacturer’s instructions.  The total inter-assay variability, according to the 
instructions, ranged from 6.8% to 29.2% for samples. 
Pharmacokinetics (PK). Blood samples were collected on treatment days 7, 14, 42, 
and EOT. Collection was targeted 24 h after the start of the infusion or the p.o. dose the 
previous day (i.e., trough concentration). Full 24-hour profiles were obtained from a 
subset of 8 patients. After collection, samples were processed immediately and stored at  
-80°C until shipment to the central research laboratory. Isavuconazole (BAL4815) 
concentrations in plasma samples were measured retrospectively using a validated LC-
MS/MS method as previously described (44). Voriconazole concentrations were not 
measured. 
Pharmacokinetic-Pharmacodynamic Analysis. A population PK-PD model was 
fitted to the data to describe the relationship between dose, drug exposure and the time-
course of GMI. Pmetrics was used for all model fitting (77). Modeling proceeded in a 
stepwise fashion because a stable solution could not be obtained when the PK and PD 
were co-modeled.  Both 1- and 2-compartment PK models that included an absorptive 
compartment were initially examined and distinguished (44). The set of differential 
equations used to describe the change in PK and PD components overtime are as follows: 
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Equation 6  
𝒅𝑿(𝟏)
𝒅𝒕
= −𝑲𝒂 ∙ 𝑿(𝟏)  
 
Equation 7  
𝑑𝑋(2)
𝑑𝑡
=  RATEIV(1) + 𝐾𝑎 ∙ 𝑋(1) − ((
𝐶𝑙
𝑉
) ∙ 𝑋(2)) 
Equation 8 
𝑑𝑋(3)
𝑑𝑡
=  𝐾𝑝𝑚𝑎𝑥 ∙ (1 − (
𝑋(3)
𝑝𝑜𝑝𝑚𝑎𝑥
)) ∙ 𝑋(3) − 𝐾𝑠𝑚𝑎𝑥 ∙ (
(
𝑋(2)
𝑉 )
𝐻𝑠
𝐸𝐶50𝐻𝑠 + (
𝑋(2)
𝑉 )
𝐻𝑠)  ∙ 𝑋(3) 
The first 2 equations describe the PK of the drug (compartment 1, theoretical 
absorptive compartment for oral administration; 2, central compartment). Clearance (CL) 
is the amount of drug being cleared from the central compartment over time and V is the 
volume of the central compartment. Ka is the first-order absorption constant. Equation 3 
describes the rate of change of the serum GMI values. Kpmax represents the maximum 
rate of GMI production, popmax is the theoretical maximum density of GMI, Ksmax is 
the maximum rate of GMI suppression, EC50 is the amount of drug where there is half-
maximal suppression of GMI, and Hs is the slope function for the GMI suppression. 
Acceptance of the final model was evaluated by visual inspection of the observed 
versus predicted values plotted over time after the Bayesian step and the coefficient of 
determination (r2) from the linear regression of the observed versus predicted values. The 
estimated bias and precision were also considered. After fitting the model to the PK-PD 
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data, the Bayesian posterior estimates for each patient were used to estimate the 
concentration–time profiles of both isavuconazole and GMI for each patient. Simulations 
were performed in ADAPT 5. Isavuconazole and GMI AUCs were calculated by 
integration from the simulated concentration–time profiles on the last day of dosing (at 
steady state) in ADAPT 5. In addition, average isavuconazole AUCs (AUCave) were 
calculated in Pmetrics by simulating the concentration-time profile for the entire dosing 
period and dividing by the days on therapy. 
The Bayesian posterior estimates for each patient’s PK were obtained. These PK 
parameter values were then fixed for each patient to enable their PD to be estimated. 
Subsequently, the mean Bayesian posterior estimates were used to calculate the area 
under the concentration-time curve (AUC) for each patient. The average AUC was 
calculated by dividing the AUC for the entire dosing duration by the total number of days 
on therapy. Since MIC was not available, we used a newly described PD index 
(AUC:EC50) to estimate drug exposure in individual patients (42).  The EC50 is the 
concentration of drug that causes half-maximal antifungal killing. The relationship 
between AUC:EC50 and the terminal GM was described using an inhibitory sigmoid Emax 
model. 
Statistical Analysis. The risk of death through Day 42 over the change in GMI at Day 
7 and 14 was estimated using the Cox proportional hazards model. A Goodness of Fit test 
is used to check the violation of proportional hazards assumption. In this test, if the 
proportional hazards assumption holds for the covariate (GMI change), then the related 
Schoenfeld residuals will not be related to event time. The Goodness of Fit test p-values 
for each model were above 0.05 indicate that the fitted Cox models hold the proportional 
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hazard assumption. The overall response by EOT was analyzed using a logistic 
regression model for change in GMI. Not all individuals had GMI measured at each day; 
therefore, to calculate the above GMI changes, the GMI value of each individual per day 
was predicted from a joint event-time and longitudinal GMI model. Mortality through 
Day 42 and overall response at the EOT included time-to-death and time-to-dropout, 
respectively, as the event-time outcome in each joint model. Dropout was defined if 
overall response was assessed prior at 84 days. Joint models are effective methods 
compared with classical linear mixed models to assess longitudinal GMI data.  Two data 
sources of data are modeled simultaneously so that the underlying dependence between 
the longitudinal GMI and event-time is explicitly acknowledged (91-93). The joint model 
consisted of a linear model with individual-level intercept, slope and quadratic terms in 
the random effects model for the time course of GMI and Cox proportional hazard model 
for the event-time and took the form: 
Equation 9  
𝑦𝑖(𝑡) = 𝛽0 + 𝛽1𝑡 + 𝛽2𝑋 + 𝑈0𝑖 + 𝑈1𝑖𝑡 + 𝑈2𝑖𝑡
2 + 𝜀𝑖(𝑡) 
Equation 10  
𝜆(𝑡) = 𝜆0(𝑡) exp(𝛾(𝑈0𝑖 + 𝑈1𝑖𝑡 + 𝑈2𝑖𝑡
2)) 
where 𝑦𝑖(𝑡) are longitudinal GMI at time 𝑡, 𝑋 is the covariate for treatment 
(1=isavuconazole; 0=voriconazole) with regression parameter 𝛽2, 𝛽0 and 𝛽1 are 
population-level (fixed) intercept and slope parameters, respectively, 𝑈 are the 
corresponding random effects, 𝜀 accounts for measurement error in the time course of 
GMI, 𝛾 allows the association between GMI and event-time, and 𝜆(𝑡) is the hazard rate 
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of event. We used joineR library in R language to fit joint models and “coxph” and “glm” 
functions in R language were used to fit the Cox and logistic regression models 
respectively.. 
For both assessments, we analyzed the total population primarily and then compared 
the two treatment groups. Prior to the analysis, the baseline co-morbidities were reviewed 
to evaluate for any imbalances between the isavuconazole and voriconazole populations. 
Results  
Overview of Patient Characteristics. The original study included 527 patients with 
185 ITT patients (71%) having positive baseline serum GMI (48). Of these, 158 mITT 
patients (79 isavuconazole-treated and 79 voriconazole-treated) were available. Seventy-
eight of the isavuconazole-treated patients with plasma concentrations were eligible for 
the PK-PD sub-analysis. The patient demographics and baseline characteristics are 
summarized in Table 4. The isavuconazole-treated patients included numerically more 
patients with hematological malignancies, allogeneic hematopoietic stem cell transplant, 
use of T-cell immunosuppressants, use of corticosteroids, and neutropenia at baseline. 
The median white blood cell (WBC) count at baseline was lower (0.3 versus 0.4 x 109 
cells/liter; p=0.0152); however, this difference is not likely clinically relevant. Baseline 
median GMI in the isavuconazole group were significantly lower (0.8 versus 1.2; 
p=0.0011). Except for a significant difference in gender (p=0.0022), the remaining 
demographics were similar between the 2 treatment groups.  
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Table 4 Patient Demographics and Characteristics at Baseline   
 Isavuconazole 
N=79 
Voriconazole 
N=79 
Total 
N=158 
p-value 
(Chi-squared 
test) 
Sex     
Male 36 (46%) 56 (71%) 92 (58%) 0.0022 
Female 43 (54%) 23 (29%) 66 (42%)  
Race     
White 67 (85%) 56 (71%) 123 (78%)  
Asian 11 (14%) 23 (29%) 34 (22%)  
Other 1 (1%) -- 1 (1%)  
Age (years)     
Mean ± SD 52.4 ± 16.1 50.7 ± 15.2 51.5 ± 15.7  
Weight (kg)     
Mean ± SD 68.4 ± 14.6 69.9 ± 14.6 69.2 ± 14.6  
Underlying Disease     
Hematological Malignancy 77 (97%) 70 (89%) 147 (93%) 0.0563 
Active Malignancy 60 (76%) 59 (75%) 119 (75%) 1.0 
Allogeneic HSCT 27 (34%) 19 (24%) 46 (30%) 0.2203 
Baseline Neutropenia 62 (78%) 55 (70%) 117 (74%) 0.2762 
T-cell Immunosuppressants 40 (51%) 34 (43%) 74 (47%) 0.4254 
Use of Corticosteroids 15 (19%) 11 (14%) 26 (16%) 0.5198 
Baseline GMI     
Median (range) 0.8 (0.1 – 6.2) 1.2 (0.5 – 9.7) 1.0 (0.1 – 9.7) 0.0018 
Duration of Therapy (days)     
Mean ± SD 50.2 ± 31.0 51.6 ± 31.6 50.9 ± 31.2  
Min-Max 5-85 2-88 2-88  
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Median 53 53 53  
Abbreviations: N: number; SD: standard deviation; HSCT: hematopoietic stem cell transplantation 
The efficacy outcomes for the 2 treatment groups were comparable to the primary 
study analyses (48). However, the numerical differences in the outcomes were reflective 
of the higher number of immunosuppressed patients in the isavuconazole group (Table 
5).   
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Table 5 All-Cause Mortality through Day 42 and Overall Response at the End of 
Therapy  
 Isavuconazole 
N=79 
Voriconazole 
N=79 
Total 
N=158 
95% CI;  
p-value 
All-Cause Mortality 
through Day 42 
16 (20%) 12 (15%) 28 (17.7%) -8.1, 20.3%; 
0.5320 
Successful Overall 
Response at EOT 
26 (33%) 30 (38%) 56 (35.4%) -21.2, 11.1%; 
0.6178 
Abbreviation: EOT: end of therapy 
Change in GMI by Survival Status Through Day 42. The joint event-time 
longitudinal model predicted the Day 7 GMI very closely compared to measured values 
in the subset of subjects with available data, Pearson correlation coefficient 0.90, 
p=0.0001 (Figure 6A-E), increasing confidence about the associations between Day 7 
GMI change and outcomes, even if Day 7 GMI was not measured in all patients. The 
average observed and predicted longitudinal trajectories for the outcomes are almost 
identical (Figure 6A and B). Residuals display no obvious systematic pattern (Figure 
6C and D), for the 42-day mortality and scatter plots were similar for the overall 
outcome). There is strong agreement between the predicted GMI and observed GMI at 
Day 7; the correlation coefficients were 0.89 and 0.91 (p < 0.0001) based on a log scale 
and original GMI scale, respectively, for the 42-day mortality (Figure 6E), and the 
values were similar for the overall response.  
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Figure 6 A-E Model statistics for joint event-time longitudinal model-predicted 
Day 7 GMI  (A and B) Joint event-time longitudinal model predicted Day 7 GMI for 
mortality and overall response, respectively. (C, D, E) Model statistics demonstrating the 
acceptable predictions produced by the model for the predicted ay 7 GMI values. 
  
 
(A) (B) (C) 
  
(D) (E) 
 
GMI steadily increased for the patients that died. The values for the patients that 
survived remained below 1.0, steadily declining during therapy (Figure 7).   
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Figure 7 Predicted GMI mean profile from the joint model with treatment as a 
covariate in the longitudinal component for the overall population. Time=Day 0 is 
the time when a patient died (cases) or had last follow-up alive (controls). GMI values 
were predicted at each day before event (death/alive). Negative values correspond to days 
before event. 
  
 
Changes in GMI by Day 7 (i.e. model-predicted Day 7 GMI minus baseline GMI) for 
the patients who died (Figure 8A) were more positive than for those that survived 
(Figure 8B). A 3- and 1.7-fold increase in the risk of death was found for each unit 
increase in GMI from baseline to Day 7 [Hazard Ratio (HR) 3.008; 95% confidence 
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interval (CI) 1.993, 4.541; p<0.0001] (test statistic 0.282 (p = 0.207)) and Day 14 [HR 
1.69; 95% CI 1.368, 2.087; p<0.0001] (test statistic 0.327 (p = 0.119)), respectively. 
Figure 8 Change in GMI at Day 7 from Baseline for patients who (A) died and 
(B) survived (Overall population). (A) Frequency of change in GMI value by Day 7 for 
patients that died. (B) Frequency of change in GMI value by Day 7 for patients that 
survived. 
A.  
 
B.  
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If GMI was treated categorically, an increase in GMI by Day 7 of more than 0.25 
GMI units from baseline increased the overall risk of death nearly 10-fold higher than 
those patients with GMI changes ≤0.25 at Day 7 (test statistic 0.029 (p = 0.878)). The 
change in GMI of >0.25 from baseline to Day 14 predicted an overall 8-fold risk of death 
[HR 8.37; 95% CI 0.120, 3.748; p<0.0001] (test statistic 0.001 (p = 0.996)). 
Because of differences in the underlying co-morbidities between the two treatment 
groups, we focused the analysis on the total population of patients rather than compare 
the two treatment groups. In patients that died, the GMI was higher among 
isavuconazole-treated patients (Figure 9). Neutropenia was assessed using a linear 
mixed-effects model for the longitudinal measures of GMI with an interaction term 
between neutropenia and drug arms. No prominent differences were found between 
drugs, neutropenic status, and GMI over time (p=0.1127).  
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Figure 9 Observed GMI mean profile for each treatment group in the 
longitudinal component. Time=Day 0 is the time when a patient died (cases) or had last 
follow-up alive (controls). Mean GMI values were computed at each day before event 
(death/alive). Negative values correspond to days before event. (Left) Patients treated 
with isavuconazonium sulfate, (Right) Patients treated with voriconazole. 
 
 
Change in GMI by Overall Response at the End of Therapy. The GMI at the EOT 
was also higher in patients that failed therapy compared to those with a successful overall 
response (Figure 10). For GMI increases of one unit from baseline to Day 7, the odds of 
successful overall response were reduced by half. Conversely, if the GMI decreased one 
unit by Day 7, the success rate more than doubled (odds ratio (OR)=2.154, 95% CI 1.173, 
3.955). If the GMI decreased by more than 0.25 units, the successful overall response was 
increased by approximately 43% compared to that if GMI increased, although this change 
was not significant (p=0.0704). By Day 14, the success rate decreased by 35.5% for every 
unit increase in GMI (p=0.0318). If the GMI decreased by more than 0.25 units, the 
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success rate increased by approximately 21% compared to that if GMI increased, 
although this change was not significant (p=0.2360). 
Figure 10 Predicted Mean GMI profile at the end of therapy for patients with a 
successful overall response (black line) and those that failed (dashed line). Time 0 
represents the assessment day (end of therapy). (Overall population) 
 
Pharmacokinetic-Pharmacodynamic Characteristics of Isavuconazole-Treated 
Patients. Seventy-eight isavuconazole-treated patients with positive baseline GMI had 
plasma concentrations and serial GMIs during therapy available for the PK-PD analysis. 
A 1-compartment model plus an absorptive compartment fitted the data well. Visual 
inspection of the observed versus predicted concentration values was acceptable. The 
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coefficient of determination (r2) of predictions based on median Bayesian posterior 
parameter values for each subject was 0.829 and estimates of bias and imprecision were 
also acceptable (0.164 and 1.04, respectively).  
The Bayesian posterior parameter estimates from the population PK model were 
calculated for each patient and included as fixed covariates in the data file. The fit of the 
linked PK-PD model to the data was good (see Figure 11A and Figure 11B). The 
coefficient of determination of the linear regression of observed-predicted values (r2) 
after the Bayesian step was 0.859. Visual inspection of the observed-versus-predicted 
concentrations were acceptable and measures of bias and imprecision were reasonable    
(-0.155 and 0.328, respectively).  
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Figure 11 A and B. Regression plot of the observed (y-axis) versus model 
predicted (x-axis) plots from the linked PK-PD model for PK (A) and GMI (B). (A) 
Logistic regression of the observed versus predicted plasma concentrations. Coefficient 
of determination (r2) of 0.829. Measures of bias and imprecision of 0.164 and 1.04, 
respectively. (B) Logistic regression of the observed versus predicted GMI values: 
Coefficient of determination (r2) of 0.859. Measures of bias and imprecision of -0.155 
and 0.328, respectively. Dotted lines represent the line of unity and open circles represent 
the individual values. 
A.  
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B.  
The parameter estimates from the final model for PK and PD are summarized in the 
Table 6.  
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Table 6 Mean and standard deviations (SD) values for each parameter estimated 
from the linked population PK-PD model  
Parameter (units) Mean SD 
Ka (h-1) 4.85 3.77 
Cl/F (L/h) 2.08 0.93 
V/F (L) 274.74 233.35 
Kpmax (GMI/h) 0.01 0.03 
Hs  14.80 5.35 
EC50 (mg/L) 0.90 1.46 
Ksmax (GMI/h) 0.01 0.04 
IC (GMI) 1.27 1.55 
Popmax (GMI) 5.24 2.34 
SD, standard deviation; Ka, the first-order rate constant describing the movement of drug from the gut to the central 
compartment; Cl, clearance from the central compartment; F, bioavailability; V, volume of the central compartment; 
Kpmax, the maximum rate of GM production, Hs, the slope function for suppression; Ksmax, the maximum rate of GM 
suppression, EC50, the amount of drug where there is half maximal suppression; IC, initial condition of GMI prior to 
drug exposure; Popmax, the theoretical maximum density of GMI. 
The relationship of the exposure to the predicted GMI at the EOT is shown in Figure 
12. An AUC:EC50 of 108.6 or more resulted in a GMI <0.5. No relationship between 
change in GMI by Day 7 or GMI at the EOT and average exposure (AUCave) was 
demonstrated, consistent with previous analyses (94).  
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𝐸𝑓𝑓𝑒𝑐𝑡 = 7.2 − (
6.9 (𝐴𝑈𝐶:𝐸𝐶502.8)
35.12.8 + 𝐴𝑈𝐶:𝐸𝐶502.8
) 
Figure 12 Inhibitory sigmoid Emax curve demonstrating the PK-PD relationship 
of isavuconazole AUC:EC50 and GMI values at the end of treatment (terminal 
GMI). Logistic regression resulted in an r2 of 0.237. Solid line represents the sigmoid 
curve fit of the model to the data, black squares represent the observed GMI values for 
each patient, and GMI negative value is included as a dotted line. 
 
Discussion  
We demonstrated that early changes in GMI (within 1 week) are significantly linked 
to clinical response and mortality. An increase in GMI after 1 week of therapy >0.25 
GMI units is associated with a ~ 10-fold increased risk of death compared to patients who 
had no change from baseline, decreased GMI, or had an increase of <0.25 units. Based on 
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the Platelia GM assay performance, 0.25 units is within the range of inter-assay 
variability.  However, our results suggest that this threshold of response by Day 7 is 
predictive of clinical response and mortality. Moreover, for any 1-unit increase in GMI 
from baseline to Day 7, the risk of mortality increases 3-fold. These results can now be 
used in a prospective study examining GM for directing antifungal therapy. If by the end 
of week 1 of treatment the GMI is increasing, and is >0.25 above the baseline value, 
treatment could be modified.  
All-cause mortality in SECURE was 19.4% (48). In this subset, the rate was similar 
(17.7%); however, the number of deaths was just over a quarter of the number in the 
original study (28 versus 100 patients). Even with smaller numbers, the p values 
describing the significance of GMI change by Day 7 in predicting outcome are quite low, 
suggesting that attributable mortality associated with IA as per increasing GMI is 
relatively high.  
This analysis is consistent with previous studies in which serial GMI measurements 
were correlated with patient outcomes. A meta-analysis of > 20 studies showed that a 
negative GMI within 1 week of outcome assessment is highly correlated with survival 
and successful outcome (alive or death without findings of aspergillosis at autopsy) (20). 
Most reports have consistently reported that increasing GMI during therapy correlate 
with unsatisfactory clinical responses or mortality (18, 19, 21, 38-40, 95). In contrast to 
another analysis of a clinical trial where a correlation was found for overall response but 
not for 12-week survival (39), we report a change in GMI by the end of week 1 was 
significantly higher for patients that died through Day 42 and in patients who had a 
failure in overall response at the EOT. In our study, a GMI change of >0.25 at 2-weeks 
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was significantly associated with mortality but not overall response. In each analysis, the 
association of GMI changes by Day 14 was not as strong as Day 7. As per Chai et al, 
status of the underlying disease and co-morbidities are increasingly powerful 
determinants of the final outcome with the passage of time (39). 
Together with clinical care of patients with IA, these findings will be helpful for 
designing and assessing clinical trials of new anti-Aspergillus agents in GM positive 
patients. An increasing GMI of >0.25 after the first week of therapy could be validated, 
as an early marker of ultimate clinical failure and trigger a change in therapy, the addition 
of another agent, or an increase in dosage. A GMI <0.5 of >2 weeks duration was highly 
correlated with successful response and this has been proposed as a potential clinical trial 
endpoint (18). We did not find a specific GMI cut-off value that linked with outcome at 
the end of week 1. Rather, our analyses suggested that early stabilization of GMI was 
highly correlated with an increased likelihood of successful outcome and survival, 
suggesting that an individual patient may not require absolute negativity of their GMI 
early in therapy to achieve ultimate therapeutic success. 
For the subset of patients with isavuconazole concentrations, we estimated the 
AUC:EC50 that results in a negative GMI at the EOT. We were unable to define a 
relationship between traditional measures of drug exposures (e.g. Cmin and AUC) and 
either clinical response or survival (96). Our inability to identify a threshold of exposure 
(e.g. AUCave) linked with response (change in GMI) could be because the regimen used 
in the trial provided exposures above those where thresholds are detectable (i.e. drug 
exposures had already elicited maximal antifungal responses). 
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We used a newly described PD index of AUC:EC50 for our analysis because the MIC 
is rarely available for patients with IA. The EC50 is the estimated in vivo drug 
concentration that is required for half maximal antifungal killing.  The EC50 requires 
some skills in PK-PD modeling and is estimated directly from the data rather than in the 
laboratory.  It is an in vivo MIC where the patient declares what drug concentrations (s)he 
requires to adequately treat their individual disease.  The AUC:EC50 provides an 
alternative way of evaluating the exposure-response relationships in the absence of a MIC 
for the invading pathogen, provided a biomarker, such as GMI, exists to determine the 
response of the organism to the drug concentrations. 
Beyond drug, factors such as impaired host function, persistent neutropenia, dosage 
and duration of corticosteroids, immunosuppressive therapies, GVHD, and concomitant 
infections (e.g. CMV viremia) could drive poor outcomes. These factors cannot be 
accounted for in model equations. Thus, the results should be interpreted carefully.  
Of the 185 patients with positive baseline GMI that were enrolled in the clinical trial, 
only 158 had serial GMI values and were included in this analysis. A review of the non-
included patients was conducted to evaluate the potential for selection bias. The only 
reason for the exclusion of these patients was due to the missing serial GMI values after 
baseline, which were required for the analysis. All of the non-included patients had 
proven or probable IA. The largest proportion (65%) of the patients not included 
discontinued prior to the protocol requirement for serial GMI (D14). The median 
treatment duration of the patients not included was 7.5 days (range 1-84 days). Fifty 
percent of these cases died on or before day 42 compared to 18% for the population of 
patients included in the analysis. Often in research, missing data are imputed to reduce 
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the impact of selection bias. However, in the case of missing biomarker data such as 
GMI, it is inappropriate to impute. 
In conclusion, our analyses suggest that early trends in GMI are highly predictive of 
the ultimate therapeutic outcome. Increases in GMI by the end of the first week after 
therapy could trigger a change in treatment. Further validation is required to determine if 
the results hold. Such information may improve the likelihood of improved clinical 
responses and survival for a disease for which therapeutic outcomes remain persistently 
suboptimal. 
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Chapter 5 Isavuconazole Population Pharmacokinetic Analysis Using 
Non-Parametric Estimation in Patients with Invasive Fungal Disease: 
Results from the VITAL Study  
 
Abstract  
Background. Isavuconazonium sulfate, a water-soluble prodrug of the triazole 
antifungal agent, isavuconazole, is available for the treatment of invasive aspergillosis 
(IA) and invasive mucormycosis (Astellas Pharma Inc, Cresemba® [isavuconazonium 
sulfate] 2015, http://www.astellas.us/docs/cresemba.pdf).  
Methods. A population pharmacokinetic (PPK) model was constructed using non-
parametric estimation to compare the pharmacokinetic (PK) behavior of isavuconazole in 
patients treated in the phase 3 VITAL open-label clinical trial, which evaluated the 
efficacy and safety of the drug for treatment of renally-impaired IA patients and in 
patients with invasive fungal disease (IFD) caused by emerging moulds, yeasts, and 
dimorphic fungi. Covariates examined were body mass index (BMI), weight, race, impact 
of estimated glomerular filtration rate (eGFR) on clearance (CL), and impact of weight 
on volume. PK parameters were compared based on IFD type and other patient 
characteristics. Simulations were performed to describe MIC covered by the clinical 
dosing regimen.  
Results. Concentrations (n = 458) from 136 patients were used to construct a 2-
compartment model (first-order absorption and central compartment). Weight-related 
covariates affected clearance, but eGFR did not. PK parameters and intersubject 
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variability of Cl were similar across different IFD groups and populations. Target 
attainment analyses demonstrated that the clinical dosing regimen would be sufficient for 
total drug area under the concentration-time curve (AUC):MIC targets ranging from 50.5 
for Aspergillus spp. (up to CLSI MICs of 0.5 mg/L) to 270 to 5,053 for Candida albicans 
(up to MICs of 0.125 and 0.004 mg/L, respectively) and 312 for non-albicans Candida 
spp. (up to MICs of 0.125 mg/L). The estimations for Candida spp. were exploratory 
considering that no patients with Candida infections were in the current analyses. (The 
VITAL trial is registered at clinicaltrials.gov under NCT00634049.) 
Conclusion. We constructed a PPK model with a goal to evaluate the exposures 
across different patient populations. We did not find significant differences between the 
populations of IFDs and different populations. It is important to continue to investigate 
the PK characteristics and exposure in critically ill patients to ensure exposures are 
adequate. 
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Introduction  
Isavuconazonium sulfate is the water-soluble prodrug of the novel, broad-spectrum, 
triazole antifungal agent isavuconazole and is available in cyclodextrin-free intravenous 
(i.v.) and oral (p.o.) formulations (78). The US Food and Drug Administration and 
European Medicines Agency recently approved isavuconazole for the treatment of 
invasive aspergillosis (IA) and invasive mucormycosis (IM). The approval in the 
European Union for mucormycosis is for patients for whom amphotericin B is 
inappropriate. Many of the pharmacokinetic (PK) analyses reported to date are limited to 
healthy volunteers and patients treated for IA. There is a paucity of data regarding the 
population pharmacokinetics (PPK) in patients with a variety of invasive fungal 
infections and underlying diseases.  
In vitro data for isavuconazole have demonstrated broad spectrum activity against a 
variety of fungi, including Aspergillus spp., Candida spp., Mucorales, Cryptococcus spp., 
and dimorphic and other rare fungi (50). In vivo models have also been conducted, 
demonstrating concentration-dependent antifungal activity for the treatment of invasive 
pulmonary aspergillosis, disseminated aspergillosis, disseminated candidiasis, 
mucormycosis, and cryptococcal meningitis (15, 51, 52, 54, 97). The VITAL clinical trial 
evaluated the efficacy and safety of isavuconazole for treatment of a variety of invasive 
fungal diseases (IFD), including the treatment of IA in patients with renal impairment and 
treatment of patients with diseases caused by emerging moulds, yeasts, and dimorphic 
fungi. Isavuconazole demonstrated successful outcomes for patients with IA and IM, with 
all-cause mortality rates through day 42 of 12.5% and 37.8%, respectively, for these 
patients. Successful outcomes have also been reported for patients with IA and renal 
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impairment, and for patients with infections caused by Cryptococcus spp., dimorphic 
fungi (such as Coccidioides spp., and Paracoccidioides spp.), Fusarium spp., and 
Scedosporium spp. (49, 55-59, 98). 
A previous PPK analysis was conducted using isavuconazole concentration-time data 
collected from nine phase 1 pharmacokinetic (PK) studies of healthy subjects and the 
phase 3 SECURE trial of patients with IA (47). These analyses demonstrated that a 3-
compartment model fit the data well (absorption, central, and peripheral compartments). 
The PK profiles were similar between healthy subjects and patients with IA. In addition, 
isavuconazole demonstrated linear PK over the range of dosages (40–400 mg) that were 
examined. 
An understanding of the PK of novel compounds in various patient populations is a 
first critical step for optimal clinical use. The phase 3 VITAL trial provides the 
opportunity to compare PK characteristics of a population of patients infected with a 
variety of fungal pathogens. This is especially important for critically ill or severely 
immunosuppressed patients and in circumstances where organ function is compromised. 
In the current analysis, we constructed a PPK model for patients enrolled in the phase 3 
VITAL trial, with the goal of comparing PK across the different patient populations to 
further understand the optimal use of isavuconazole. 
Materials and Methods  
Study design. The VITAL trial (ClinicalTrials.gov identifier: NCT00634049) 
evaluated the efficacy and safety of isavuconazole for the treatment of proven or probable 
IA in patients with renal impairment and for treatment of patients with proven or 
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probable IFD caused by Mucorales and other emerging moulds, yeasts, and dimorphic 
fungi. Patients were eligible whether they required primary therapy or were refractory or 
intolerant to their previous systemic antifungal therapy. Patients received a loading 
regimen of either i.v. or p.o. isavuconazonium sulfate at a dose of 372 mg (equivalent to 
200 mg isavuconazole) every 8 h for the first 48 h, followed by i.v. or p.o. 
isavuconazonium sulfate 372 mg once daily for up to a maximum of 180 days. The 
institutional review board at each center approved the study protocol, and all research 
subjects provided written informed consent. 
Plasma PK sampling. Blood samples were collected from each patient on treatment 
days 7, 14, 42, and at the end of therapy. Collection was targeted at the time point 24 h 
after the start of the infusion or the p.o. dose the previous day (i.e., trough concentration). 
Full 24-h profiles were obtained from a subset of 33 patients. After collection, samples 
were processed immediately and stored at –80°C until shipment to the central research 
laboratory. 
Bioanalytical analysis. Isavuconazole (BAL4815) and inactive cleavage product 
(BAL8728) concentrations in plasma samples were measured using a validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method at PPD, LLC 
(Pharmaceutical Product Development, LLC, Middleton, WI, USA). A plasma sample 
volume of 50 μL was combined with the internal standard (d4-
isavuconazole/pyridooxazinone) and subjected to protein precipitation using acetonitrile. 
Following centrifugation for 10 min at 5°C, 75 µL of the supernatant was isolated for 
dilution with water:formic acid:ammonium hydroxide (1000:10:0.5, 
vol/vol/vol)/acetonitrile (850:150, vol/vol) and then submitted for analysis. 
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Chromatographic separation was achieved using a Synergi Polar-RP column (20 mm by 
2.0 mm by 4 µm, Phenomenex, Torrance, CA, USA) with a gradient mobile phase 
consisting of water, acetonitrile, methanol, and formic acid. An API3000 mass 
spectrometer (AB Sciex, Framingham, MA, USA) in positive ion mode was used to 
monitor the analytes. Multiple-reaction monitoring transitions were m/z 438.1→224.1 for 
isavuconazole, 165.0→121.2 for inactive cleavage product, 442.1→224.1 for d4-
isavuconazole, and 151.1→123.2 for pyridooxazinone. The validated curve range was 5 
to 1,250 ng/mL for both isavuconazole and inactive cleavage product, and any samples 
measuring above the upper limit were diluted 5-fold, 10-fold, or 20-fold prior to analysis. 
The lower limit of quantification (LOQ) was 5 ng/mL. Inter-assay precision (coefficient 
of variation [%]) of the BAL4815 quality control samples (12.5, 25, 75, 250 and 1,000 
ng/mL) was 6.1%, 4.6%, 3.1%, 2.5%, and 2.6%, respectively, while the inter-assay 
accuracy (relative error, [%]) were 2.4%, 3.6%, 3.1%, 2.3%, and 0.2%, respectively.  
Interassay precision of the BAL8728 quality control samples (12.5, 25, 75, 250 and 1,000 
ng/mL) was 7.0%, 7.1%, 5.9%, 8.5%, and 6.5%, respectively, while the interassay 
accuracy was -1.9%, -0.4%, -1.0%, 2.1%, and 2.8%, respectively. All study samples were 
analyzed within the established long-term stability of the drug (isavuconazole) (955 days 
at –70°C). All PPK analyses were conducted on the isavuconazole concentrations due to 
the lack of antifungal activity of the cleavage product.  
PPK Modeling. A PPK model was developed using nonparametric estimation in 
Pmetrics software (v1.3.2, University of Southern California, Los Angeles, CA, USA) 
(77). The model-fitting process included evaluations of both 2- and 3-compartment 
models, including absorptive compartments with and without a lag-time. Data were 
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weighted by the inverse of the estimated assay variance. Acceptance of the final model 
was evaluated by visual inspection of the observed versus predicted concentration values 
before and after the Bayesian step, the coefficient of determination (r2) from the linear 
regression of the observed versus predicted values, and estimates for bias (mean weighted 
error) and imprecision (adjusted mean weighted squared error). 
The impacts of body mass index (BMI), weight, and race (Asian versus other) on 
clearance, and of weight on volume were initially assessed as covariates by visual 
inspection of the graphical representation of each covariate versus clearance and volume 
to evaluate for inclusion in the final model. The covariates were chosen based on results 
of previous PPK studies with isavuconazole (99). In addition, this study permitted the 
enrollment of patients with renal impairment, in contrast to the phase 3 SECURE trial. 
Therefore, the impact of estimated glomerular filtration rate (eGFR) on clearance was 
also evaluated. The eGFR was calculated using serum creatinine level and the 
“modification of diet in renal disease” formula. 
The average daily area under the concentration-time curve (AUCavg) for each patient 
was calculated using the Bayesian posterior parameter estimates from the final model 
using the trapezoidal rule in Pmetrics. AUCavg was calculated by determining the total 
AUC over the entire dosing period and dividing it by the number of days of therapy for 
each patient. The patients were subclassified according to the type of IFD diagnosed at 
baseline and baseline underlying disease. The PK parameters of the patient subsets were 
evaluated separately and compared with the overall data set and with those from the 
previously reported PPK model with isavuconazole (99). Statistical comparisons were 
performed in MYSTAT 12 (version 12.02; Systat Software, Inc.; http://www.systat.com). 
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Simulations of 5,000 patients were performed in Pmetrics to assess the probability of 
target attainment (PTA) for the approved clinical dosing regimen to achieve the various 
total drug AUC:MIC pharmacodynamic (PD) targets estimated from preclinical models 
for different organisms (i.e., A. fumigatus, C. albicans, C. glabrata, and C. tropicalis) 
(52, 100, 101). The choice to use total drug AUC:MIC targets was considered acceptable 
since protein binding is similar between humans and the animal models used to estimate 
the targets. 
Results  
Study population. In total, 458 isavuconazole concentrations from 136 patients were 
included in the model. Table 7 summarizes the key patient demographics and clinical 
characteristics. The majority of the patients were white. The mean (± standard deviation 
[SD]) weight and BMI were 70.2 ± 19.5 kg and 24.4 ± 5.9 kg/m2, respectively. Fifty-
three patients (39%) had an eGRF < 60 mL/min/1.73 m2 at baseline, and the mean eGFR 
for the total population was 80.2 mL/min/1.73 m2. A total of 65 patients (48%) had one 
or more of the following: hematologic malignancy, active malignancy, or baseline 
neutropenia. Forty-one percent (n = 56) of the overall population had hematologic 
malignancies, and 30% (n = 41) had active malignancy at enrollment. One-fourth (n = 
34) of patients were neutropenic (absolute neutrophil count [ANC] values of <500/mm3) 
at baseline. Twenty-four of 65 patients with hematologic malignancies had all three 
baseline characteristics combined, 13 patients were described as having active 
hematologic malignancies at baseline and five had both hematologic malignancies and 
baseline neutropenia. Fourteen were reported as having only hematologic malignancies, 
four had only active malignancies, and five had only neutropenia. Seventy-one patients 
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did not have any of the three characteristics reported at baseline. Further, 17% had 
received an allogeneic hematopoietic stem cell transplant, and the use of T-cell 
immunosuppressants and corticosteroids was reported in 41% and 24% of the overall 
population, respectively. In addition to IM (n = 34) and IA (n = 20), the analysis included 
patients with IFD caused by other fungal pathogens as summarized in Table 7. After IM, 
the next most commonly enrolled IFDs were caused by dimorphic fungi, such as 
Coccidioides spp., Paracoccidioides spp., and Histoplasma spp.  
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Table 7 VITAL patient demographics and clinical characteristics  
Patient population (n) 
No. of patients 
 
 
White Asian Black Other Body weight (kg) a BMI (kg/m2) a 
Overall (136) 100 23 9 4 70.2 ± 19.5 24.4 ± 5.9 
Patients with infection       
IA (20) 18 2 0 0 68.0 ± 20.7 23.2 ± 4.7 
IM (34) 23 8 3 0 73.4 ± 18.6 25.3 ± 5.5 
Other filamentous fungi and 
moulds (23) 
17 4 2 0 72.8 ± 25.0 25.1 ± 7.1 
Dimorphic (29) 20 4 2 3 64.2 ± 16.1 23.0 ± 5.8 
Non-Candida yeasts (10) 5 3 1 1 61.9 ± 11.7 22.2 ± 3.3 
Mixed infection (13) 11 1 1 0 75.0 ± 18.7 26.1 ± 7.5 
No pathogen identified (7) 6 1 0 0 79.2 ± 20.4 27.7 ± 5.6 
a Data are mean ± SD. 
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A 2-compartment model which included a first-order absorptive compartment fit the 
data well. Figure 13 shows a schematic of the structural model. Compartment 1 
represents the absorptive compartment (i.e., gut) and compartment 2 represents the 
central compartment. 
Figure 13 Illustration of the structural model. The boxes represent the modeled 
compartments (1=theoretical absorptive compartment and 2=central compartment). The 
arrow connecting compartment 1 and 2 shows the flow of drug from the gut to the central 
compartment. The arrow from the central compartment represents elimination of drug 
from the central compartment at a rate associated with CL over V. Abbreviations: CL, 
clearance; F, oral bioavailability; Ka, first-order absorption rate constant; Tlag, lag-time; 
V, volume in the central compartment. 
 
 
 
  
The fit of the PPK model was acceptable based on visual inspection of the observed 
versus predicted plots and the coefficient of determination (r2) of 0.89 for the observed 
versus the posterior predicted values after the Bayesian step (Figure 14). The estimates 
of bias and imprecision were also acceptable (–0.0539 and 2.77, respectively). Evaluation 
of a 3-compartment model did not result in a better fit of the model to the data.  
Nbolus (1) 
RATEIV(1) 
V 
CL/V 
Ka 
F 
Tlag, F 
2 1 
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Figure 14 Observed versus posterior predicted concentrations (mg/L) from the 
final model after the Bayesian step. Statistics: r2= 0.89, slope = 1.05 [95%CI 1.01 to 
1.08], intercept = -0.0484 [95%CI −0.179 to 0.0825]. The dotted line is line of unity 
where observed concentrations equal predicted concentrations. 
  
There was not a statistically significant impact of eGRF and Asian ethnicity on 
clearance (Figure 15a and Figure 16). However, for BMI and weight, the 95% 
confidence interval (CI) of the slope did not include zero, suggesting statistical 
significance (Figure 15b and Figure 15c). Weight was found to have a significant impact 
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on the volume of the central compartment (r2 and slope were 0.06 and 2.36 [95% CI, 0.69 
to 4.02], respectively) (Figure 15d).  
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Figure 15 Linear regression plots charting the impact of covariates on clearance 
and volume. (A) eGFR on clearance (r2 and slope for each were 0.02 and 0 [95% CI 0 to 
0.01], respectively) did not suggest a correlation. (B) BMI on clearance (r2 and slope for 
each were 0.06 and 0.07 [95% CI 0.02 to 0.11], respectively) suggested a significant 
relationship. (C) Weight on clearance (r2 and slope for each were 0.06 and 0.02 [95% CI 
0.01 to 0.03], respectively) found a significant relationship. (D) Weight on volume in the 
central compartment (r2 and slope for each were 0.06 and 2.36 [95% CI 0.69 to 4.02], 
respectively) suggested a significant correlation. 
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Figure 16 Impact of Asian race on clearance. Box plots for the clearance values for 
Asian patients (n=23) (median = 1.59 L/h) versus other patients (i.e., non-Asian; includes 
white, black, or African-American, and “other”; n=113) (median = 1.84 L/h) did not 
show a statistically significant difference (P = 0.06, Mann-Whitney U test). 
  
These covariates were then incorporated into the structural model to determine if their 
inclusion helped to better describe interpatient variability. Only one size-related covariate 
(weight) was included, since other measures, such as BMI, are less practical measures in 
clinical settings. Inclusion of the covariates did not improve fitting, as assessed by 
minimal changes in –2 log likelihood (decrease of 3 points) and Akaike's information 
criterion (increase of 5 points), as well as by visual comparisons of the observed versus 
predicted concentration-time plots for each patient. Therefore, the base model was used 
for further evaluation of model performance. 
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The mean (± SD) parameter estimates for the overall population and classified 
according to IFD type are shown in Table 8. The mean clearance for the entire 
population was 2.5 ± 1.6 L/h and the mean AUCavg was 87.1 ± 41.0 mg·h/L. The mean 
values for clearance and AUCavg ranged from 2.0 to 3.2 L/h and 70.4 to 94.0 mg·h/L, 
respectively, for the individual IFD types. The intersubject variability of clearance was 
63% overall. AUCavg and clearance values across the different types of IFD were similar 
(P = 0.420 and 0.248, Kruskal-Wallis nonparametric test). The mean estimate for 
bioavailability was 96.6% for the overall population (median 98.2%). 
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Table 8 Isavuconazole PPK parameters in VITAL study, based on infection  
Patient population (n) 
CL (L/h) 
(mean ± SD) 
V (L) 
(mean ± SD) 
AUCavg (mg·h/L) 
(mean ± SD) 
%CV  
of CL 
F (%) 
Overall (136) 2.5 (± 1.6) 361.2 (± 166.3) 87.1 (± 41.0) 63 96.6 
Patients with infection      
IA (with renal impairment) (20) 2.3 (± 1.5) 412.2 (± 222.4) 92.0 (± 44.0) 64 97.4 
IM (34)  3.0 (± 2.0) 364.1 (± 186.0) 87.7 (± 56.9) 68 95.0 
Other filamentous fungi and moulds (23) 2.2 (± 0.9) 344.2 (± 99.7) 80.6 (± 29.2) 41 96.9 
Dimorphic fungal infection (29) 2.0 (± 1.3) 343.0 (± 159.6) 94.0 (± 36.7) 62 97.5 
Non-Candida yeasts (10) 2.5 (± 1.4) 318.2 (± 160.8) 92.0 (± 29.5) 55 94.9 
Mixed infection (13) 3.2 (± 2.0) 389.8 (± 162.7) 70.4 (± 24.0) 62 97.7 
Patients with no pathogen identified (7) 2.3 (± 1.6) 340.4 (± 107.5) 87.8 (± 29.1) 68.7 98.2 
CL, clearance; V, volume in the central compartment; %CV, percent covariance on the intersubject variability; F, bioavailability. 
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A further review of the PK characteristics was also explored across the different 
underlying diseases (Table 9). Clearance values were comparable for patients with 
hematologic malignancies, active malignancies, or baseline neutropenia and patients 
without these conditions (P = 0.530, Kruskal-Wallis one-way analysis of variance). The 
mean clearance and AUCavg values for patients with hematologic malignancies were 2.8 
L/h and 85.1 mg·h/L, respectively. Patients with a combination of hematologic 
malignancy, baseline neutropenia, and active malignancy also had similar values (2.8 L/h 
and 85.1 mg·h/L for clearance and AUCavg, respectively). Bioavailability did not vary 
significantly across the different underlying disease groups. Intersubject variability of 
clearance was consistent across the underlying disease groups and similar to the overall 
population values, with values ranging from 59% to 62%. 
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Table 9 Isavuconazole PPK parameters in the VITAL, based on underlying diseasea  
Underlying disease (n)b 
CL (L/h) 
(mean ± SD) 
V (L) 
(mean ± SD) 
AUCavg (mg·h/L) 
(mean ± SD) 
%CV of 
CL 
F (%) 
Overall (136) 2.5 (± 1.6) 361.2 (± 166.3) 87.1 (± 41.0) 63 96.6 
Hematologic malignancy (56) 2.6 (± 1.6) 378.7 (± 171.0) 85.1 (± 50.2) 60 96.2 
Active (at baseline) malignancy (41)  2.6 (± 1.6) 382.2 (± 165.3) 84.4 (± 54.0) 59 95.9 
Baseline neutropenia (34) 2.7 (± 1.8) 406.3 (± 168.0) 82.8 (± 57.9) 59 96.0 
Combined hematologic malignancy, active 
(at baseline) malignancy, baseline 
neutropenia (24) 
2.8 (± 1.8) 391.7 (± 187.2) 85.1 (± 68.0) 62 94.7 
Nonec (71) 2.8 (± 1.8) 391.8 (± 187.2) 85.1 (± 68.0) 62 94.7 
a CL, clearance; V, volume in the central compartment; %CV, percent covariance on the inter-subject variability; F, bioavailability. 
b Patients in each category are not mutually exclusive.  
c Patients without hematologic malignancy, active (at baseline) malignancy, or baseline neutropenia. 
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The total drug AUC:MIC ratio is the PK-PD index that appears to best link 
isavuconazole exposure with efficacy in preclinical models (100, 101) and PD targets 
have been defined for both Aspergillus spp. and Candida spp. in a range of preclinical 
models (52, 100, 101). Steady-state AUCs (at day 21) for 5,000 simulated subjects were 
assessed over a range of MICs to determine the ability of the clinical dosing regimen to 
achieve the various PD targets as a function of the known MIC distribution. For 
Aspergillus spp., the PD target estimated by Seyedmousavi and colleagues (100) for A. 
fumigatus was a total drug AUC:MIC value of 50.5. For Candida spp., Lepak and 
colleagues (101) established targets in neutropenic mice for C. albicans (total drug 
AUC:MIC = 5,053) and non-albicans Candida (total drug AUC:MIC = 312). Figure 17 
shows the MIC coverage for each PD target for the isavuconazonium sulfate clinical 
dosing regimen. Each graph illustrates the proportion of 5,000 simulated subjects 
achieving each of the PD targets at each MIC value after administration of the clinical 
dosing regimen of isavuconazonium sulfate. Depending on the species, the clinical 
dosing regimen would be predicted to adequately cover Clinical and Laboratory 
Standards Institute MIC values of 0.5 mg/L or lower for A. fumigatus and 0.004 and 
0.125 mg/L or lower for C. albicans and non-albicans Candida spp., respectively. The 
same analysis was conducted using PD targets from an additional PK-PD model that was 
reported for isavuconazole and C. albicans (52). In this model, PD target values of 270 
and 670 were estimated depending on the extent of neutropenia (temporary or persistent, 
respectively). If these total drug AUC:MIC targets are used for the PTA analysis, the 
results would demonstrate that the clinical dosing regimen will achieve the target for the 
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majority of C. albicans MIC distribution (up to MICs of 0.125 to 0.06 mg/L, 
respectively), which has a MIC90 of 0.06 mg/L. 
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Figure 17 PTA (left y-axis) for PD targets estimated in PK-PD animal models for 
the common fungal pathogens. (A) A. fumigatus, (B) non-albicans Candida, and (C) 
C. albicans  The blue line shows the frequency (%) of the 5000 simulated subjects that 
would achieve the PD target at each MIC value after administration of the clinically 
recommended dosage of isavuconazonium sulfate (372 mg every 8 hours for days 1 and 
2, followed by 372 mg once daily thereafter). Isavuconazole CLSI MIC frequency 
distributions (right y-axis) are provided for (A) A. fumigatus (n = 855), (B) C. glabrata (n 
= 254) and C. tropicalis (n = 130), and (C) C. albicans (n = 844); represented by the red 
bars. 
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Discussion  
Nonparametric estimation was used to establish a PPK model for isavuconazole by 
using Pmetrics and plasma drug concentrations collected from phase 3 clinical trial 
patients being treated for a variety of IFDs. A 2-compartment model including an 
absorptive compartment with first-order absorption fit the data well. Evaluation of the 
B  
C  
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impact of covariates on clearance revealed a statistically significant relationship with 
BMI and weight but no relationship between either eGFR or Asian race and clearance. 
Weight also had a significant relationship with volume of the central compartment. 
However, inclusion of the covariates in the structural model did not improve the fit of the 
model to the data. This is likely due to a weak relationship compared with the relatively 
large unexplained PK variability. The overall population parameters did not differ greatly 
from the individual IFD types or across the underlying diseases evaluated, even for 
severely immunocompromised patients. 
We further assessed the adequacy of currently approved regimens by conducting PTA 
analyses using PD targets defined from experimental models for specific fungal 
pathogens. The results were consistent with previous data reported for Aspergillus spp. 
(99). For Candida spp., this represents the first report of a PTA analysis conducted using 
the PD targets for Candida spp. Importantly, however, this study did not include patients 
with invasive candidiasis. The majority of such cases occur in the context of critical 
illness, where the PK may be reasonably different and have an impact upon both the PD 
and PTA. Further analyses must be performed to characterize any differences in PK for 
patients with invasive candidiasis and then determine if these differences have any impact 
on the exposure coverage of the MIC distribution for these organisms. The isavuconazole 
MIC50 and MIC90 for C. albicans were 0.002 and 0.06 mg/L, respectively, for a collection 
of 844 isolates (102-114). For the non-albicans Candida spp. tested in the PK-PD model 
of disseminated candidiasis, the isavuconazole MIC50 and MIC90 were 0.03 and 1 mg/L 
for C. tropicalis (n = 130) and 0.06 and 1 mg/L for C. glabrata (n = 254) (102-114). If no 
differences in the PK of isavuconazole exist for patients with candidemia or invasive 
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candidiasis and the patients described herein, the current analysis suggests that the 
clinical dosing regimen will achieve the PD target reported by Lepak and colleagues 
(101) for the majority of the non-albicans Candida spp. but not for C. albicans. However, 
a second model, which evaluated the PD target for C. albicans, was also explored and 
gave difference results (52). These total drug AUC:MIC targets demonstrated that the 
clinical dosing regimen would achieve the target for the majority of the C. albicans MIC 
distribution (up to MICs of 0.125 and 0.06 mg/L). For other important fungi, such as 
organisms of the Mucorales order, Cryptococcus spp., and dimorphic fungi, validated in 
vivo PK-PD models have not been fully established. This demonstrates a clear knowledge 
gap for optimizing therapy for life-threatening infections with these organisms. 
A previous PPK model was conducted for isavuconazole by using parametric 
estimation in NONMEN 7.2 software (47), using plasma concentration data from nine 
trials involving healthy subjects and one large phase 3 clinical trial of patients with IA or 
infections with other filamentous fungi (SECURE trial). Desai et al. (47) employed a 
Weibull absorption function and did not estimate the lag time and bioavailability. In our 
analysis, a 2-compartment model with an absorptive compartment was better than a 3-
compartment model with an absorptive compartment as previously described by Desai. 
This is likely due to sparse sampling for the large majority of patients. Regardless of the 
differences between the two structural models, the mean clearance values estimated from 
both models are similar (2.5 L/h versus 2.4 L/h). Important patient characteristics that 
potentially have an impact on drug exposure were also explored. We did not identify 
differences in the heterogeneous population based on IFD type and underlying diseases. 
The intersubject variability of clearance was consistent among the populations, even for 
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the severely immunocompromised (i.e., patients with hematologic malignancy, active 
malignancy, and neutropenia combined at baseline). 
We did not find a statistically significant relationship between race and clearance, in 
contrast to a previous report by Desai et al. that race (Asian) is associated with reduced 
clearance (47). The relationship between race and clearance in the current data may not 
have been seen because of the differences in sample size. The current analysis included 
23 Asian patients, whereas the study of Desai et al. included 53 Asian patients. Desai et 
al. suggested that the influence of race-dependent CYPs on clearance is likely to be 
minimal because isavuconazole is not a substrate of CYP2D6 or CYP2C19 isoenzymes 
(47). However, additional pharmacogenetic studies are required to further elucidate the 
potential impact of race on clearance and drug exposure. Desai et al. did not report a 
relationship for weight and clearance but did find a relationship between BMI and 
volume. Both race and weight impacts on clearance and weight impacts on volume were 
included in the final model. While we identified significant covariates, inclusion of the 
covariates in the structural model did not significantly change the model fit to the data. 
The reasons for this could be that the size of the Asian population and range of weights in 
the data set were not large enough to significantly affect the model or that the 
relationships of these covariates to clearance and volume are not strong.   
We report the AUCavg for the population by calculating the total AUC for the dosing 
duration and dividing it by the number of days of therapy. It is important to note that the 
average treatment duration of therapy for the population in the PK data set was only 14 
days, compared to the average duration for the study, which was 135 days. Therefore, the 
values for AUCavg reported here are slightly lower than they would be if we were 
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reporting steady-state AUC. The population mean estimate of AUCavg was 87.1 mg·h/L, 
and the mean steady-state AUC for the 5,000 simulated patients was 94.4 mg·h/L. This 
was comparable to the mean estimates obtained for each of the individual IFD types and 
to that obtained for the patients from the SECURE trial (47).  
Isavuconazole clearance and AUC were not different across the various IFD and 
underlying diseases from the VITAL trial and were similar to the reported clearance and 
AUC values from patients with IA in the SECURE analyses (47). The values for 
intersubject variability of clearance across the populations, even for the small group of 
patients with severe immunosuppression, and between the VITAL and SECURE studies 
were similar, further illustrating the predictability of the PK of isavuconazole in most 
patients. For comparison, the reported intersubject variability of AUC for posaconazole 
ranges from 62 to 80% and that for voriconazole ranges from 120-168%, depending on 
the formulation administered and patient population studied (115, 116).  
Most of the patients in this analysis were receiving numerous concomitant 
medications. A comprehensive review of the concomitant medications and the potential 
impact on the plasma concentrations was not performed. This could be a limitation in the 
analysis and the ability to detect differences may be influenced by this missing 
information. However, in principle, the study design excluded the use of medications 
known to significantly change the plasma concentrations of isavuconazole; and therefore, 
is not felt to have influenced the study results greatly.  
PTA analysis offers an estimate of the coverage of MIC values provided by the 
clinical dosing regimen for common fungal pathogens. The results suggest that for the 
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most common pathogens for which PD targets have been estimated, the clinical dosing 
regimen provides adequate coverage of the majority of the wild-type distribution of A. 
fumigatus, A. flavus, and A. terreus strains, and the results support previous PTA analyses 
(99) for these organisms. For C. albicans and non-albicans Candida spp., the results 
suggest reasonable coverage of the isavuconazole MIC distribution from a large 
collection of in vitro susceptibility studies. However, further analyses are necessary to 
characterize the PK characteristics for patients infected with invasive candidiasis and 
candidemia. This is especially important given recently completed phase 3 clinical trial of 
the treatment of candidemia did not meet the primary endpoint of overall response at the 
end of the intravenous isavuconazole therapy compared to caspofungin (117). If there are 
PK differences in critically ill patients treated for candidemia and invasive candidiasis, 
this may affect the outcome of the clinical breakpoint selection, and potentially the 
recommended dosing regimen for treatment of invasive candidiasis.  
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Chapter 6 The Impact of Mucositis on Absorption and Systemic 
Drug Exposure of Isavuconazole  
 
Abstract  
Background. Isavuconazonium sulfate is the water-soluble prodrug of isavuconazole. 
Population analyses have demonstrated relatively predictable pharmacokinetic (PK) 
behavior in diverse patient populations. We evaluated the impact of mucositis on the oral 
isavuconazole exposure using population PK modeling.  
Methods. We evaluated patients treated in two phase 3 trials of isavuconazole, 
SECURE for treatment of invasive aspergillosis (IA) and other filamentous fungi and 
VITAL for patients with mucormycosis, invasive fungal disease (IFD) caused by other 
rare fungi, or IA and renal impairment. Mucositis was reported by site investigators and 
its impact on oral bioavailability was assessed. Use of the oral formulation was at the 
discretion of the investigator. Patients with plasma samples collected during the use of 
isavuconazonium sulfate were included in the construction of population PK model. 
Results. Of 250 patients included, 56 patients had mucositis at therapy onset or as an 
adverse event during oral isavuconazole therapy. Oral bioavailability was comparable of 
98.3% and 99.8%, respectively. The average drug exposures (AUCave) calculated from 
either the mean or median parameter estimates were not different between patients with 
and without mucositis. Mortality and overall clinical response was similar between 
patients receiving oral therapy with and without mucositis.  
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Conclusion. Isavuconazole exposures and clinical outcomes in this subset of patients 
with mucositis who were able to take oral isavuconazonium sulfate were comparable to 
those without mucositis, despite the difference in oral bioavailability. Therefore, 
mucositis may not preclude use of the oral formulation of isavuconazonium sulfate. 
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Introduction  
Invasive mould diseases (IMDs) are life-threatening conditions that require timely 
and intensive treatment. Patients with hematological disorders or who have undergone 
hematopoietic stem cell transplantation (HSCT) are a leading risk group for IMDs. Anti-
neoplastic chemotherapy for acute myeloid leukemia (AML) or acute lymphocytic 
leukemia (ALL) and conditioning regimens for HSCT often cause mucosal disruption of 
the gastrointestinal (GI) tract (i.e. mucositis) that may compromise oral bioavailability 
(118). An evaluation of the impact of mucositis on the oral absorption of antifungal 
agents is required to ensure optimal antifungal therapy (119). 
Isavuconazonium sulfate, the water-soluble prodrug of the triazole antifungal agent 
isavuconazole, is approved by the US FDA for the treatment of invasive aspergillosis 
(IA) and invasive mucormycosis (IM) and by the EMA for the treatment of IA, and for 
IM in patients for whom amphotericin B is inappropriate (43, 120). The clinical 
formulations include both intravenous and oral capsules. The pharmacokinetics have 
been well characterized from sub-studies embedded in clinical trials (44-47). The pivotal 
clinical trials included more than 400 patients with >60% with hematological 
malignancies or other conditions that required intensive chemotherapy and the potential 
for mucositis (48, 49).   
Here, we examine the impact of mucositis on the bioavailability and drug exposure 
following the administration of oral isavuconazonium sulfate.  We fitted a population 
pharmacokinetic model to the plasma concentrations from patients receiving oral 
isavuconazole in patients with and without mucositis and used this model to evaluate 
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bioavailability and the ultimate drug exposure.  We consider the potential impact for 
dosing and therapeutic drug monitoring of isavuconazole in the setting of mucositis. 
Methods  
Study design. Patients treated with isavuconazonium sulfate from two Phase 3 
clinical trials, SECURE and VITAL, were eligible for inclusion if plasma concentrations 
were available. The SECURE trial (ClinicalTrials.gov identifier: NCT00412893) 
evaluated the efficacy and safety of isavuconazole compared with voriconazole for the 
primary treatment of invasive mould disease caused by Aspergillus spp. and other 
filamentous fungi (48). The VITAL trial (ClinicalTrials.gov identifier: NCT00634049) 
evaluated the efficacy and safety of isavuconazole for the treatment of IA in patients with 
renal impairment and in patients with IFD caused by Mucorales and other emerging 
moulds, yeasts, and dimorphic fungi (49). Eligibility criteria for both studies are detailed 
elsewhere (48, 49). Patients received a loading regimen of isavuconazonium sulfate at a 
dose of 372 mg (equivalent to isavuconazole 200 mg) every 8 h for the first 48 h. In the 
SECURE trial, the loading dose was required to be administered intravenously (i.v.), 
while in the VITAL trial treatment could commence using either the i.v. or oral 
formulation. The maintenance regimen for both studies was i.v. or oral isavuconazonium 
sulfate 372 mg once daily for up to 84 or 180 days, respectively. Patients received i.v. or 
oral drug at the discretion of site investigators. 
Identification of Patients with Mucositis. The medical history (MH) and adverse 
event (AE) records from the case report forms were reviewed for MedDRA preferred 
terms suggestive of “mucositis” or “stomatitis” (e.g. mucosal inflammation, radiation 
mucositis, stomatitis, gastrointestinal inflammation). From there, the patients were further 
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reviewed to determine the degree of likelihood that the MH and AE reported represented 
significant disease, such as recent radiation therapy or intensive chemotherapy. Patients 
with mucositis were only included if administration of the oral formulation occurred 
during the episode of mucositis AND plasma PK concentrations coincided with the oral 
administration and episode of mucositis. Patients without mucositis with plasma PK 
measurements during oral administration were classified as non-mucositis patients. 
Plasma PK sampling. Blood samples were collected on treatment days 7, 14, 42, and 
end of therapy (EOT) in both trials. Collection was targeted for 24 hours after the start of 
the infusion or the oral dose on the previous day (i.e., trough concentration). Full 24-hour 
profiles were obtained from a subset of 43 patients (including 6 patients with mucositis). 
After collection, samples were processed immediately and stored at –80°C until shipment 
to the central research laboratory. Isavuconazole concentrations were measured at the 
completion of the study using a validated LC-MS/MS method as previously described 
(44). 
Population Pharmacokinetic (PPK) Modeling. Raw plasma concentration data from 
the 2 groups during oral administration that was collected after Day 7 were compared to 
determine if any trends in the data were observed. A PPK model was developed using 
non-parametric estimation using Pmetrics (v1.4.1, University of Southern California, Los 
Angeles, CA, USA) (77). The model-fitting process included evaluation of both 2- and 3-
compartment models including absorptive compartments and a lag-time. The presence of 
mucositis (yes=1, no=0) was used as a covariate on oral bioavailability (F) as a secondary 
equation, which took the following form: 
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Equation 11  
𝐹 = 𝐹1 ∙ (1 − 𝑀𝑈𝐶) +  𝐹12 ∙ 𝑀𝑈𝐶 
where, F1 refers to the oral bioavailability in patients without mucositis (MUC=0) and 
F12 refers to the oral bioavailability in patients with mucositis (MUC=1).  
Data were weighted by the inverse of the estimated assay variance. The final model 
was assessed by a visual inspection of the observed-versus-predicted concentration values 
before and after the Bayesian step, the coefficient of determination (r2) from the linear 
regression of the observed-versus-predicted values, as well as estimates for bias (mean 
weighted error) and precision (adjusted mean weighted squared error).  
The average AUC (AUCave) for each patient was calculated using the Bayesian 
posterior parameter estimates from the final model using the trapezoidal rule in Pmetrics. 
AUCave was calculated by determining the total AUC over the entire dosing period and 
dividing by the number of days of therapy for each patient. Statistical comparisons were 
performed in MYSTAT 12 version 12.02 (https://systatsoftware.com) and GraphPad 
Prism version 6.0h (http://www.graphpad.com). 
Exposure-Response Analysis. The AUCave for patients with and without mucositis 
were compared by patient outcomes defined as All-Cause Mortality through Day 42 or 
Overall Response to explore if any impact on exposure was associated with differences in 
response. Statistical comparisons were performed in MYSTAT 12 (version 12.02, 
http://www.systat.com). 
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Results  
Study Population. A total of 250 patients were included in the analysis of which 56 
had mucositis. Figure 18 shows the flow of patient inclusion in the study.  
Figure 18 Flowchart illustrating flow of isavuconazole-treated patients into the 
mucositis and non-mucositis populations  
  
The majority of the mucositis patients had a hematologic malignancy (89.3%) that 
was active at the time of enrollment and were neutropenic at the start of antifungal 
treatment (78.2%) (Table 10). Only 6 patients did not have a hematological malignancy 
[aplastic anemia (n=3), uterine leiomyosarcoma (n=1), X-linked adrenomyeloneuropathy 
(n=1), squamous cell carcinoma of the tongue (n=1)]. A quarter (26.8%) of the patients 
with mucositis had received a HSCT. Sixteen percent of mucositis patients had baseline 
404 enrolled 
(258 SECURE + 146 VITAL)
286 with plasma concentrations
92 with mucositis
Mucositis Population:
n=56 (received PO during mucositis 
episode)
4 IV only
32 mucosotis 
onset after 
treatment or no 
PK during PO
Non-Mucositis Population:
n=194
118 without plasma concentrations
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renal impairment (eGFR-MDRD < 60 mL/min/1.73m2) compared with 27.6% of those 
without mucositis. The majority of the overall population were males (62%), Caucasian 
(78.8%), and the average age (± SD) and weight (± SD) were 50.3 ± 16.1 years and 70.0 
± 18.3 kg, respectively. 
Table 10 Demographics, Background Disease and Duration of Therapy  
 Mucositis 
N=56 
Non-Mucositis 
N=194 
Total 
N=250 
Age (years)    
Median (min-max)  50 (18-79) 52 (19-92) 52 (18-92) 
Sex    
Male 32 (57%) 123 (63%) 155 (62%) 
Race    
White 48 (86%) 149 (77%) 197 (79%) 
Asian 7 (13%) 31 (16%) 38 (15%) 
Black 1 (2%) 9 (5%) 10 (4%) 
Other 0 5 (3%) 5 (2%) 
Weight (kg)    
Mean ± SD 71.7 ± 18.1 69.5 ± 18.4 70.0 ± 18.3 
Underlying Disease    
Hematological Malignancy 50 (89.3%) 101 (52.1%) 151 (60.4%) 
Active Malignancy 40 (71.4%) 76 (39.2%) 116 (46.4%) 
Allogeneic HSCT 15 (26.8%) 33 (17.0%) 48 (19.2%) 
Baseline Neutropenia 43 (78.2%) 64 (41.8%) 107 (51.4%) 
T-cell Immunosuppressants 23 (41.8%) 82 (51.9%) 105 (49.3%) 
Use of Corticosteroids 8 (14.3%) 47 (24.2%) 55 (22.0%) 
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Duration of Therapy (days)     
Median (range)    
Total duration 75.5 (8-735) 83 (1-882) 82 (1-882) 
IV formulation 9 (2-45) 7 (0.5-77) 7.5 (0.5-77) 
Oral formulation 58 (1-690) 79.8 (0.5-882) 73 (0.5-882) 
 
Type of Fungal Infection in Patients with Mucositis. Thirty-two patients had proven 
or probable IA and 7 patients had possible IA (with appropriate host factors, clinical 
features but no mycological evidence of disease). Eight patients had proven or probable 
infection caused by various mould and rare yeasts including Mucorales (n=1), Fusarium 
spp. (n=3), Culvularia lunata (n=1), Alternaria spp. (n=1), Acremonium spp. (n=1), and 
Trichosporon spp. (n=1). Five patients did not have enough evidence for probable or 
proven IFD after review of the Data Review Committees. 
PPK Model. Comparisons of the raw plasma concentrations for the patients with 
mucositis and patients without mucositis during oral administration beyond Day 7 
revealed a statistical difference between the 2 groups (p-value = 0.0011) (Figure 19), 
although the concentrations largely overlapped. A 2-compartment model including an 
absorptive compartment fit the data well.   
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Figure 19 Comparison of plasma concentrations drawn during oral 
administration after day 7 of therapy between the mucositis and non-mucositis 
patients. Comparison of the plasma concentrations between patients without mucositis 
(non-mucositis) and patients with mucositis (p-value = 0.0011; Mann-Whitney U test, 
non-parametric) 
 
 
An illustration of the structural model is provided in Figure 20 where the first 
compartment represents the gut (oral compartment) and the second representing the 
central compartment.   
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Figure 20 Illustration of the Structural Model. Compartment 1 represents the gut 
for oral administration (box on left); Compartment 2 represents the central compartment 
(box on right); Arrow between compartments 1 and 2 represents drug flow from the gut 
to the central compartment. The arrow from the central compartment represents 
elimination of drug at a ratio of CL/V. Abbreviations: CL, clearance; F, bioavailability; 
Ka, first-order absorption rate constant; Tlag, lag-time; V, volume in the central 
compartment; RATEIV(1) specifies infusions going directly into the central 
compartment. 
  
 
 
 
 
The fit of the model to the data was acceptable based on visual inspection of the 
observed-versus-median predicted plots and the coefficient of determination (r2) of 0.813 
after the Bayesian step (Figure 21). The estimates of bias and imprecision were also 
acceptable (0.11 and 0.938, respectively). The observed-versus-mean predicted plots 
showed similar statistics with a coefficient of determination (r2) of 0.792 (slope = 0.976) 
after the Bayesian step.  
Nbolus (1) 
RATEIV(1) 
V 
CL/V 
Ka 
F 
Tlag, F 
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Figure 21 Observed versus median posterior predicted concentrations (mg/L) 
from the final model after the Bayesian step.  Statistics: r2= 0.813, slope = 0.98 
[95%CI, 0.956 to 1], intercept = -0.0181 [95%CI, −0.115 to 0.0792]. Dotted line is line of 
unity where observed concentrations equal predicted concentrations. 
  
 
The median parameter estimates are included in Table 11. 
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Table 11 Median Parameter estimates from the PPK model  
 Mucositis Non-Mucositis 
 Mean ± SD Median Range %CV Mean ± SD Median Range %CV 
Ka (h-1) 7.0 ± 2.6 7.9 0.0-8.0 38% 6.5 ± 3.0 7.9 0.0-8.0 46% 
Cl/F (L/h) 2.2 ± 1.0 1.9 0.5-4.1 44% 2.3 ± 1.1 1.9 0.1-5.9 47% 
V/F (L) 331.4 ± 154.9 347.7 6.8-895.5 47% 354.1 ± 182.5 349.8 5.8-895.5 52% 
Lag time (h) 1.2 ± 1.2 1.0 0.0-5.0 94% 1.3 ± 1.3 1.0 0.0-5.0 103% 
F (%) 86.0 ± 18.5 98.3 50.3-99.7 21% 97.4 ± 6.9 99.8 70.2-99.9 7% 
AUCave  (mg·h/L) 105.3 ± 55.9 91.9 45.9-315.5 53% 114.1 ± 141.2 100.2 30.8-1944.3 124% 
Abbreviations: SD, standard deviation; Ka, first-order absorption rate constant; CL, clearance; F, bioavailability; V, volume in the central compartment, AUCave, average area-
under-the concentration curve. 
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Comparison of Oral Bioavailability. The mean (range) oral bioavailability (F) 
estimates for mucositis and non-mucositis patients were 86.0% (50.3-99.7%) and 97.4% 
(70.2-99.9%), respectively. Comparison of the mean and median bioavailability estimates 
for the two populations demonstrated a significant difference between the 2 groups 
(p  <  0.0001, Mann-Whitney U non-parametric Test) (Figure 22).  
Figure 22 There is a significant difference in the median estimates for 
bioavailability between the 2 groups.  Boxplot illustrating the comparison of oral 
bioavailability estimates for patients with mucositis and patients without mucositis (non-
mucositis) (p<0.0001, Mann-Whitney U Test, non-parametric). 
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However, this 11.4% difference in bioavailability did not have a significant impact on 
the distribution of exposures (AUCave) between the two groups (p=0.706, Mann-Whitney 
U Test, non-parametric) (Figure 23).  
Figure 23 No significant difference in average AUCs between mucositis and non-
mucositis patients. Boxplot illustrating the comparison of AUCave estimates for patients 
with mucositis and patients without mucositis (non-mucositis) (p=0.706, Mann-Whitney 
U Test, non-parametric). AUCs calculated from the median parameter estimates after the 
Bayesian step  
  
 
All-Cause Mortality through Day 42. All-cause mortality through treatment day 42 
for the patients with and without mucositis was 7.1% (4/56) and 14.4% (28/194), 
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respectively. The oral bioavailability and AUCave were 83.6% and 91.3 mg·h/L, 92.7% 
and 164.9 mg·h/L, 99.7% and 56.5 mg·h/L, and 99.7% and 216.9 mg·h/L for the four 
patients with mucositis who died. The median bioavailability estimates for the non-
mucositis patients that died were all above 90% except for one patient with an estimate of 
70.2%. The mean AUCave was 100.5 mg·h/L and ranged from 34.9-369.1 mg·h/L. 
Overall Response at the End of Therapy (EOT). Overall Response at the EOT was 
available for 232 mITT patients in the analysis. Fifty-eight percent [n=43; 95% CI 42.13, 
72.99] and 42.9% [n=189, 95% CI 35.68, 50.42] of the patients with and without 
mucositis had a successful response, respectively. In the mucositis patients who failed at 
the EOT (n=25), the mean oral bioavailability was 84.9 ± 17.9%, (range 50.4-99.7%; 
median 90.3%) and the mean AUCave was 117.9 ± 69.4 mg·h/L, (range 45.9-315.5 
mg·h/L; median 94.2 mg·h/L). Six of the patients (n=18; 33%) who failed at the EOT had 
oral bioavailability estimates < 80% (range 50.4-69.5%) with AUCave values ranging 
from 45.9-176.3 mg·h/L and 8 of the patients (n=25; 32%) with successful responses at 
the end of therapy had bioavailability estimates of <80% (range 50.3-75.5%) with 
AUCave ranging from 48.2-155.2 mg·h/L. 
Discussion  
Biological factors that have an impact on drug absorption include the pH along the GI 
tract, tissue perfusion, the presence of bile and mucus, the surface area per volume of the 
lumen, and the epithelial integrity. Mucositis manifests as erythema, inflammation, 
ulcerations, and hemorrhage of the mucosal surfaces of the GI tract and causes gastric 
motility dysfunction. This mucosal disruption can significantly affect drug absorption 
after the oral administration of medications. Using oral medications in the setting of 
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mucositis requires an understanding of the determinants of drug absorption. 
Table 12 summarizes the determinants of oral bioavailability for triazole antifungal 
agents. Isavuconazole and fluconazole have similar characteristics that include the 
absence of clinically relevant effect on absorption from food, changes in pH, or increases 
in GI motility (43, 121, 122). Posaconazole and itraconazole oral solutions should be 
administered with high-fat meals, carbonated soda, or nutritional supplements (119, 123-
128).  Plasma concentrations are decreased when gastric acidity is reduced (119, 123-
128). Absorption of posaconazole oral solution may be improved when daily doses are 
fractionated compared with less frequent dosing (129). The newer posaconazole tablets 
are not affected by changes in gastric pH and absorption is not improved by the 
consumption of high-fat meals (126, 130). Voriconazole plasma concentrations are 
reduced when taken with food; however, absorption is not clinically significantly affected 
by changes in pH or by drugs such as omeprazole (131). H2-blockers were not found to 
cause clinically significant changes in voriconazole absorption kinetics (132).  
Voriconazole exhibits decreased oral bioavailability in patients with cystic fibrosis (CF) 
compared to patients without CF after lung transplant (133). Thus, factors that affect the 
absorption of triazoles such as mucositis differ markedly. 
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Table 12 Comparison of factors impacting oral absorption of triazole antifungal drugs  
 
Isavuconazonium 
sulfate 
Voriconazole Posaconazole (124) Itraconazole (125) 
Fluconazole 
(122) 
Formulation capsule tablets solution tablets solution capsule tablet 
Water 
Solubility 
Y (prodrug) N N N Y 
Bioavailability 
(%) 
     
Healthy 
Subjects 
98 (121) 96 (134) 8-48 (fasted) 54 (fasted) 55 90 
Patients 97 (44) 64 (135)    
GI motility 
agents 
none No data found Decreases none No data found No data found 
pH Effect none none 
Decreases in 
reduced acidity 
none 
Decreased in reduced 
acidity 
none 
Food Effect none Decreases concentrations 
Increases 
concentrations 
(especially high 
Cmax and 
AUC increases 
16% and 51% 
Increases 
concentrations 
none 
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fat, nutritional 
supplement or 
acidic carbonated 
beverage) 
with high fat 
foods 
Other  
F significantly lower in 
CF lung tx (23%) pts 
versus non-CF lung tx 
(63%) (133); 2 factors 
significant association 
with F in lung tx pts: CF, 
post-operative time 
(increased with 
increasing time) (133) 
Divided doses 
increases 
absorption 
   
Substrate of 
Pgp 
no no yes yes yes yes no 
Abbreviations: Y: yes; N: no; GI: gastrointestinal; F: bioavailability; CF: cystic fibrosis; Pgp: P-glycoprotein 
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Drugs that require food to increase bioavailability or experience decreased 
bioavailability with increased gastric emptying (increased gastric motility) suggest that 
passive diffusion is slow and likely occurs primarily from the stomach. In these 
circumstances, absorption is improved by longer transit times in the stomach and upper 
small intestine. Aside from the prodrug formulation of isavuconazole, the other azoles are 
limited by the insufficient dissolution in stomach prior to delivery in the duodenum, 
where absorption is maximal. A meal that is high in fat increases luminal volume and bile 
and pancreatic secretions, and delays gastric emptying. The absorption for drugs such as 
posaconazole may be optimized by the use a more fractionated regimen (123, 136, 137). 
However, studies have suggested that this may be due to the high-fat meal increasing the 
solubility versus delayed gastric emptying (123). Another study failed to associate factors 
such as P-glycoprotein on the absorption of posaconazole (138). In contrast, the 
absorption for isavuconazole and fluconazole (and to a lesser extent voriconazole) is not 
significantly influenced by these factors, suggesting passive diffusion occurs more 
quickly and the majority of the absorption occurs in the upper small intestine. 
In this analysis, the presence of mucositis did not have a significant overall impact on 
the clinical outcomes in the patients treated with isavuconazonium sulfate from the 
SECURE and VITAL trials despite the statistical differences in oral bioavailability 
between the groups with and without mucositis. In addition, the drug exposure between 
the groups was not significantly different. The results held whether mean or median 
parameter estimates were used for the comparisons. 
The current study has several limitations. First, details on the presence or severity of 
mucositis were not available for the majority of patients with the condition. 
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Quantification of severity may have allowed for a deeper understanding of the impact for 
the degree of mucosal disruption and the impact on oral bioavailability. Second, patients 
were allowed to switch back and forth from oral to intravenous medication during the 
treatment period. However, only patients with mucositis coinciding with oral 
administration were selected for analysis. Third, the administration of i.v. or oral 
formulations was at the discretion of the site investigators making it difficult to assess the 
impact of the severity of mucositis on oral bioavailability.  Patients with more severe 
grades of mucositis patients may have remained on i.v. therapy longer, while patients 
with less severe mucositis may have been switched to oral therapy. In addition, 
identification of mucositis patients for this study relied on the reporting of the events by 
the treating investigator, which could be underrepresenting the incidence in the study. We 
did not utilize a validated mucositis score or a biomarker, such as citrulline to capture 
severity as has done in other studies (139). Finally, we assumed compliance was 100%, 
which may be overly optimistic.  
These analyses are important as many patients who will be treated with 
isavuconazonium sulfate are at risk or could have mucositis at the onset of therapy caused 
by the harsh treatments used to treat their underlying co-morbidities. Patients with 
slightly lower bioavailability had outcomes similar to those with higher bioavailability. 
Therefore, use of the oral formulation of isavuconazonium sulfate during episodes of 
mucositis may be acceptable; however, treating physicians may consider extending 
isavuconazole intravenous therapy during episodes of mucositis or monitoring levels to 
ensure they are within the range reported from the clinical trial. However, additional 
studies in this population may be warranted.  
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Chapter 7 Exposure-Response Analysis of Micafungin in Neonatal 
Candidiasis: Pooled analysis of two clinical trials  
 
Abstract  
Background. Neonatal candidiasis causes significant morbidity and mortality in high-
risk infants. A micafungin dosage regimen of 10 mg/kg established for the treatment of 
neonatal candidiasis is based on a laboratory animal model of neonatal hematogenous 
Candida meningoencephalitis and pharmacokinetic (PK)-pharmacodynamic (PD) 
bridging studies. However, little is known about the how these PK-PD data translate 
clinically. 
Methods. Micafungin plasma concentrations from infants were used to construct a 
population PK model using Pmetrics software. Bayesian posterior estimates for infants 
with invasive candidiasis were used to evaluate the relationship between drug exposure 
and mycological response using logistic regression. 
Results. Sixty-four infants aged 3 to 119 days old were included, of which 29 (45%) 
infants had IC. A 2-compartment PK model fit the data well. Allometric scaling was 
applied to clearance and volume normalized to the mean population weight (kg). The 
mean (SD) estimates for clearance and volume in the central compartment were 0.07 
(0.05) L/h/1.8kg and 0.61 (0.53) L/1.8kg, respectively. No relationship between AUCave 
or AUCave:MIC ratio and mycological response was demonstrated (p>0.05).  Although 
not statistically significant, mycological response was numerically higher when AUCs 
were at or above the PD target. 
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Conclusion. While an exposure-response relationship was not found, PK-PD 
experiments support higher exposures in infants with invasive candidiasis. More patients 
would clarify this relationship; however, low incidence deters the feasibility of these 
studies.  
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Introduction  
Neonatal candidiasis results in significant morbidity and mortality in premature 
infants (60-62).  The associated mortality with invasive candidiasis (IC) is three-times 
higher than that of uninfected infants of similar gestational age and birth weight (63).  
The involvement of the central nervous system (CNS) is especially detrimental for 
subsequent neurodevelopmental outcomes and mandates meticulous attention to the 
selection of safe and effective antifungal regimens (64-66). 
There is a large safety and efficacy database that supports the role of micafungin for 
the treatment of IC in both adults and children (67, 140-142). Micafungin has broad-
spectrum anti-Candida coverage and a favorable safety profile (68, 69). Micafungin 
demonstrates linear pharmacokinetics (PK), dose adjustment is not required in the setting 
of renal and/or hepatic impairment, and therapeutic drug monitoring is not required in 
any patient populations (143).  
The pharmacodynamics (PD) of micafungin for the treatment of hematogenous 
Candida meningoencephalitis (HCME) has been explored in a well-characterized 
experimental model (70). PK-PD bridging studies suggest that a neonatal regimen of 10 
mg/kg is required for effective treatment of Candida infections in the CNS (70, 72). 
These studies were used to justify the choice of this high dose regimen for treatment of 
infants with IC.  Unfortunately, however, inherent difficulties in conducting neonatal 
trials and the general decrease in the incidence of neonatal candidiasis resulted in early 
termination of one of the studies after the enrollment of only 30 infants with the primary 
and safety results reported elsewhere (144). 
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Ideally, predictions from preclinical models should be tested clinically to 
prospectively validate the PK-PD relationships. Establishing preclinical-to-clinical 
linkages are increasingly viewed as fundamental for the establishment of effective 
antimicrobial therapies. In this study, we examined the clinical relevance of reaching the 
PD target established in preclinical models. We combined micafungin plasma 
concentrations from four neonatal clinical trials to construct a population PK (PPK) 
model and then explored whether increasing micafungin drug exposures resulted in 
improved clinical outcomes in infants with IC. 
Methods  
Study Design. Micafungin plasma concentrations from four pediatric clinical trials 
were available for population PK modeling. Each study has been described in detail 
elsewhere (72, 144-147). Briefly, the dataset consists of two PK and safety studies with 
dosages ranging from 0.75 to 10 mg/kg and two efficacy, safety, and PK studies with 
dosages ranging from 2 to 10 mg/kg/day. The local Institutional Review Board/Ethics 
Committee at each site approved the studies and parental consent was obtained for each 
infant prior to initiation of study procedures within each study. Plasma sampling is 
described in the respective publications. The micafungin concentrations were analyzed 
using high performance liquid chromatography (HPLC), as detailed in the individual 
publications (72, 145, 146). Estimated gestational age was not available for all clinical 
trials so we were unable to incorporate this variable in the analysis or to use it to calculate 
other age descriptions such as post-conceptional age. 
PPK modeling. A PPK model was constructed using the population PK program 
Pmetrics (v1.5.1, University of Southern California, Los Angeles, CA, USA) (77). The 
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observations were weighted by the inverse of the estimated assay variance. Initial 
parameter estimates were anchored on two prior population PK models. The first study 
included 47 infants < 4 months which used prior knowledge from adult population PK 
modeling and standardized estimates of clearance and volume in the central compartment 
to a 70-kg adult weight (71). The second study utilized 293 pediatric patients including 
the 64 infants in the present analysis (unpublished data). This population PK model 
normalized the clearance and volume to the mean weight of the 293 pediatric patients 
based on prior knowledge from previous pediatric population PK analysis (148). The 
structural model included allometric scaling terms for clearance and volume, which were 
also standardized to the mean body weight of the population (1.8 kg). The differential 
equations for the final structural model with allometric scaling are as follows: 
Equation 12  
𝑑𝑋(1)
𝑑𝑡
=  𝑅(1) −
[
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∙ 𝑋(1) + [𝐾𝑝𝑐 ∙ 𝑋(2)] 
Equation 13  
𝑑𝑋(2)
𝑑𝑡
= 𝐾𝑐𝑝 ∙ 𝑋(1) − 𝐾𝑝𝑐 ∙ 𝑋(2) 
where CLstd and Vstd represent the normalized clearance and volume values using the 
mean body weight of the population, R represents the infusion of micafungin into 
compartment 1, Kcp and Kpc represent the rate of drug transfer to and from the central 
(compartment 1) and peripheral (compartment 2) compartments, respectively.  
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The fit of the model to the data was evaluated by visual inspection of the observed-
versus-predicted concentrations before and after the Bayesian step, and the coefficient of 
determination (r2) from the linear regression of the observed-versus-predicted values. In 
addition, the estimates for bias (mean weighted error) and imprecision (adjusted mean 
weighted squared error) were assessed. 
Bayesian posterior estimates from the best model were used to estimate area-under-
the concentration-time curve (AUC) for each patient for the entire dosing interval in 
Pmetrics using trapezoidal rule. The average daily AUC was then determined by dividing 
the total AUC for the treatment course by the number of days of micafungin therapy. 
Using daily average AUC avoids the issue of having to define what time in the course of 
therapy that AUC is important for efficacy (e.g. AUC at the end of dosing or on a specific 
day during therapy). 
Exposure-Response Analysis. A subset of 29 infants who received micafungin for the 
treatment of proven invasive candidiasis was used for the exposure-response analysis. 
Mycological response was used as an outcome measure. Successful mycological response 
was defined as eradication (documented by negative fungal cultures) through 1 week post 
the receipt of the last dose of micafungin. In most patients, after documentation of 
eradication during therapy, follow-up cultures were sparse or not performed due to lack 
of clinical need (i.e. a successful response). Therefore, an additional part of the definition 
of “successful response” was that no new antifungal therapy was required after 
completion of micafungin. Failure (persistence of infection) was defined as continued 
positive cultures or in the absence of repeat cultures, there was a requirement to switch to 
an alternative antifungal therapy for further treatment.  
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The relationship of AUCave and AUCave:MIC to mycological response (binary data) 
was analyzed using logistic regression in SAS® (version 9.3, SAS Institute Inc., Cary, 
NC, USA). The exposure parameters were added in an automated stepwise approach with 
α=0.3 for model inclusion and α=0.05 for model retention. Additional statistical 
comparisons were performed in MYSTAT 12 (version 12.02, http://www.systat.com). 
Attainment of Pharmacodynamic Targets. Drug exposures from the 29 infants with 
IC were used to verify if the 10 mg/kg dosage ensured attainment of the PD target (AUC 
and AUC:MIC ratio) representing the near-maximal effect determined in the in vivo 
rabbit model of Candida meningoencephalitis (70, 71) and to assess if achieving this 
target improved survival and/or mycological response.  
Results  
Study Population for PPK. A summary of the demographics of patients enrolled 
included from the 4 studies is provided in Table 13. Four micafungin clinical trials with a 
combined total of 64 infants aged 3 to 119 days were available. There were slightly more 
males than females (n=35 males, 55%), the mean (SD) age was 35 days (27 days), and 
the mean (SD; range) weight was 1.8 kg (1.1 kg; 0.5-4.8 kg). The treatment duration 
ranged from 1 to 34 days, with a mean (SD) of 6.8 days (7.9 days).  
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Table 13 Description of Micafungin Pediatric Studies included in the PPK model  
Study n Description Age Range 
(days) 
Weight 
Range (kg) 
Sex  
(% males) 
Dose (mg/kg) Infusion 
Duration 
Duration 
(days) 
Heresi, 2006 
(145) 
22 Single-dose PK and tolerability study 
in premature Infants requiring systemic 
antifungal 
3.6 – 61.9 0.6-2.0 60.9% 0.75, 1, and 3 30 
minutes 
1 
Benjamin, 
2010 (72) 
13 Multiple-dose PK and safety study for 
empiric therapy 
3.0 – 118.7 0.54-1.4 46.2% 7 and 10 1 hour 4-5 
Queiroz-
Telles, 2008 
(147)/ Undre, 
2012 (146) 
17 Efficacy, safety, and PK study in the 
treatment of IC 
3.6 – 94.6 0.9-3.3 64.7% 2; dose increase 
to 4 for 
therapeutic 
effect 
1 hour Up to 42 
Benjamin, 
2015 (144) 
12 Efficacy, safety, and PK study in the 
treatment of IC 
12.0 – 116.8 0.7-4.8 33.3% 10 2 hours Up to 42 
Abbreviations: PK: pharmacokinetics; IC: invasive candidiasis 
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Population PK model. A total of 287 micafungin concentrations were retrieved for 
the population PK analysis. A description of the 4 studies is included in Table 13. A two-
compartment model with allometric scaling fit the data well. A visual inspection of the 
observed-versus-predicted concentrations after the Bayesian step was acceptable with a 
coefficient of determination (r2) of 0.945 (Figure 24) using the median parameter values.  
Similar results were observed for the mean posterior predicted values (r2 = 0.941 for the 
linear regression of the observed-versus-predicted values). Estimates of bias and 
imprecision were also acceptable (-0.126 and 0.902, respectively).  
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Figure 24 Observed versus posterior predicted concentrations (mg/L) from the 
final model after the Bayesian step (A) Linear and (B) Log Scale. Upper (A): Linear 
scale (r2= 0.945, slope = 0.995 [95%CI 0.967 to 1.02], intercept = 0.24 [95%CI −0.104 to 
0.584]). Lower (B): Log scale () (r2= 0.947, slope = 0.946 [95%CI 0.92 to 0.972], 
intercept = 0.0496 [95%CI 0.0284 to 0.0709]). Dotted line is line of unity where 
observed concentrations equal predicted concentrations. 
A.  
B.   
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The mean parameter estimates are included in Table 14. The mean (SD) clearance 
and volume in the central compartment were 0.07 (0.05) L/h/1.8 kg and 0.61 (0.53) L/1.8 
kg, respectively.  
 158 
Table 14 Mean, medians, standard deviations (SD), and coefficients of variation 
(%CV) for the parameter estimates  
Parameter Clstd 
(L/h/1.8 kg) 
Vstd 
(L/1.8 kg) 
Kcp 
(h-1) 
Kpc 
(h-1) 
Mean (range) 0.07 
(0.002-0.299) 
0.61  
(0.192-2.780) 
1.74 
(0.035-5.966) 
1.92 
(0.090-5.970) 
SD 0.05 0.53 1.57 1.29 
Median 0.06 0.43 0.99 2.00 
%CV 68.8 85.9 89.9 67.1 
Abbreviations: Cl: clearance; std: standard; V: volume in the central compartment; L: liters: kg: kilogram; Kcp: 
represents rate of drug moving from the central to the peripheral compartments; Kpc: represents rate of drug moving 
from the peripheral to the central compartments 
Exposure-Response Population and Analysis. Twenty-nine infants ranging in age 
from 4 to 117 days received micafungin for the treatment of proven invasive candidiasis 
or candidemia; 17 infants received a dose of 2 mg/kg in a trial comparing micafungin to 
liposomal amphotericin B (147) and 12 infants received a dose of 10 mg/kg in a trial 
comparing micafungin to conventional amphotericin B (144). The median (range) body 
weight of the 29 infants was 1.95 kg (0.68 to 4.85 kg). The median (range) treatment 
duration was 14 days (1-34 days). Minimum inhibitory concentration (MIC) values from 
the 2 mg/kg and 10 mg/kg studies were available for all but 2 infants with values ranging 
from 0.004-2 mg/L and 0.03-2 mg/L, respectively. All but 3 patients had candidemia. The 
other 3 patients had proven infections in the urinary tract (n=2) and disseminated disease 
(n=1; eye, CSF, blood). Seventy-six percent and 92% of infants receiving 2 and 10 mg/kg 
survived, respectively. Successful mycological response was achieved in 83% and 76% 
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of patients receiving 2 and 10 mg/kg, respectively. Table 15 summarizes the exposure 
estimates (AUCave and AUCave:MIC) for the 2 and 10 mg/kg dosages from each study. 
Table 15 Estimates of AUCave and AUCave:MIC for infants less than 4 months of 
age with IC treated with micafungin at doses of 2 mg/kg and 10 mg/kg  
 AUCave  
(mg∙h/L) 
AUCave:MIC ratio 
10 mg/kg n=12 n=11 
median 401 6475 
range 198-815 115-18,675 
%CV 43% 100% 
% ≥ 166.5 mg∙h/L or 
≥  1332* 
100% 55% 
2 mg/kg n=17 N=16 
median 62 2395 
range 27-179 74-89,354 
%CV 68% 133% 
% ≥ 166.5 mg∙h/L or 
≥  1332* 
12% 56% 
*AUC0-144.5 or AUC0-144.5:MIC ratio representing the PD target for the near-maximal effect in the HCME rabbit 
model. 
The CNS PD target AUC for near-maximal effect that was demonstrated in the rabbit 
model of HCME was approximately 166.5 mg∙h/L (70, 71). All infants treated at a dose 
of 10 mg/kg achieved the CNS PD target, while only two (12%) of the infants receiving 2 
mg/kg achieved the CNS PD target (Table 16). Successful mycological response was 
achieved by 86% of patients who reached the PD target as compared to 73% of patients 
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who did not meet the PD target, but this difference was not statistically significant 
(p=0.396). Of those infants reaching the AUC:MIC ratio PD target for near-maximal 
effect of 1332, successful mycological response was achieved by 92% and 83% of those 
who reached and did not reach the target, respectively. 
Table 16 MIC Values and Treatment Response by dose groups and by patients 
that did or did not achieved the CNS PD target  
 10 mg/kg 
(n=12) 
2 mg/kg 
(n=17) 
MIC (mg/L) Range 0.03-2 0.004-2 
MIC90 2 1 
Survival 11 (92%) 13 (76%) 
Mycological Response 10 (83%) 13 (76%) 
Treatment Response in Patients Reaching PD target 
 ≥ 166.5 mg∙h/L* 
(n=14) 
≥ 1332*# 
(n=15) 
Survival 12 (86%) 11 (73%) 
Successful Mycological Response 12 (86%) 11 (73%) 
Treatment Response in Patients Not Reaching PD target 
 < 166.5 mg∙h/L* 
(n=15) 
< 1332*# 
(n=12) 
Survival 12 (80%) 11 (92%) 
Successful Mycological Response 11 (73%) 10 (83%) 
*AUC0-144.5 or AUC0-144.5:MIC ratio representing the PD target for the near-maximal effect in the HCME rabbit model. 
#Only 27 infants had MIC values to be included in this analysis. 
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There was no clear relationship between mycological response (success or failure) 
and either AUCave and AUCave:MIC when examined using logistic regression (p  >  0.05). 
Figure 25a and Figure 25b illustrates the similarity in the drug exposure measures for 
those patients with successful and failure of mycological response. 
Figure 25. Boxplot illustrating the relationship between mycological response 
and AUCave (A) and AUCave:MIC (b). Boxplots illustrating the comparison of AUC (A) 
and AUC:MIC (B) estimates for infants based on the mycological response [success (left) 
or failure (right)].  
A.   
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B.  
 
Discussion  
In the current population PK analysis, robust estimates of drug exposures for 
individual patients were obtained. However, no statistically significant relationship 
between drug exposure and treatment outcomes was demonstrated. There are several 
potential reasons for this observation. First, the number of infants (n=29) was small, and 
therefore, the study lacked adequate power to detect a difference despite the numerically 
better response rate in the group with higher exposures [86% versus 73%, p=0.396]. 
Assuming the mycological responses rates of 86% and 73% from the two groups, the 
study would require a sample size of approximately 142 to yield at least 80% power 
(two-sided, 5% significance level). Second, there is extreme heterogeneity in the clinical 
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characteristics of neonates and young infants with many factors that are extraneous to the 
infection that potentially confound outcome measures (e.g. gestational age, birth weight, 
and other concomitant co-morbidities). Third, there is significant heterogeneity in the 
clinical presentation and prognosis of Candida infections in this population. Disease may 
range from simple colonization to dissemination and devastating involvement of the 
brain. It may be possible to stratify patients to more effectively account for the 
heterogeneity; however, there simply are not adequate laboratory and clinical tools to do 
this accurately. 
Outcome measures used in these studies have a number of inherent limitations. 
Previous studies have demonstrated that infants that survive IC have poorer 
neurodevelopment outcomes compared to those without IC regardless of the presence of 
candidemia or confirmed CNS infection (66). The extent of correlation between short-
term outcome measures and longer-term neurodevelopment outcomes is not known. The 
demonstration of negative fungal cultures is central to definitions of disease resolution. 
However, the lack of sensitivity of fungal cultures (<50%) (149) impairs the clinical 
utility of this metric. Clinical signs and symptoms are neither sensitive nor specific 
enough to assess therapeutic response (150).  The strongest predictor of septicemia in one 
study was hypotension, present in less than 5% of the infants, which had only a 31% 
positive predictive value (151). All-cause mortality is obviously an important endpoint, 
but is invariably confounded by comorbidities that may swamp the signal coming from 
the drug-pathogen interaction. The use of biomarkers such as (13) β–D-glucan could 
aid in the objective assessment of the response to therapy (152, 153). These data and 
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others suggest that fungal biomarkers be included for assessment of therapeutic response 
in future clinical trials (154). 
A further problem resides in substantial difficulties in conducting clinical trials in this 
patient population. Enrollment in the micafungin clinical trials was extremely slow. For 
example, the recently terminated study enrolled only 30 of the 225 planned patients in 2 
and a half years (144). Reasons for such slow recruitment may be related to the decreased 
incidence of invasive candidiasis in this population (155). A recent study reported in 
2014 that the annual US incidence of invasive candidiasis decreased from 3.6 episodes to 
1.4 episodes per 1000 infants, from 24.2 to 11.6 episodes per 1000 infants with a birth 
weight of 750– 999 g, and from 82.7 to 23.8 episodes per 1000 infants with a birth weight 
< 750 g (155). The terminated study provides a recent example of the difficulty of 
conducting these studies (144). This study had 70 sites from 23 countries available to 
screen patients. Only half of the sites found appropriate infants to screen and only 22% of 
them were able to enroll at least one infant.  
Clinical trials may not be the most efficient way to identify safe and effective 
regimens for relatively rare fungal infections. Preclinical-to-clinical bridging studies 
represent one of the few ways regimens can be de-risked for clinical study.  Importantly, 
however, there is relatively little experience with this approach and certainly no 
consensus on the type of studies that are required.  We have recently reflected and 
summarized some of the necessary factors in a PK-PD package for the development of 
new antifungal agents in adults (156).  The same exercise now needs to be performed for 
infants.  This topic was discussed in detail at a recent FDA workshop 
(http://www.fda.gov/Drugs/NewsEvents/ucm507958.htm).  Some important factors 
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identified in the workshop include: (1) using preclinical models that are a faithful mimic 
of human neonatal disease. Such an approach enables pharmacodynamic idiosyncrasies 
in infants to be accounted for; (2) using neonatal strains and studying more than one 
strain; (3) cross validating findings from various models and understanding the reasons 
for the differences; (4) using positive controls that have a clinical indication and an 
effective regimen with enough information to enable an experimental-clinical PK-PD 
bridge. If we could build a collection of these “positive controls” for future drug 
development in infants, the performance of a new agent could be geared to compete with 
the positive control; (5) setting up experimental models that produce “on scale” readouts. 
Model behavior is governed by the chosen experimental conditions, such as strain, 
inoculum, background immunosuppression, delay in initiation of treatment, and treatment 
duration. The key thought is that clinically relevant exposures of a positive control 
induces a response in the middle of the drug exposure-response curve. 
While stating all this, clinical data from neonates is still a critical piece of finding the 
safest optimal dose.  For safety data we still need to evaluate dosing in neonates and 
models such as registries for clinicians to enter important information when rare 
conditions are treated with newer drugs and drug dosing may be another way to address 
these challenges. 
In conclusion, a statistically significant drug exposure-response relationship for 
micafungin for neonatal candidiasis was not found. However, PK-PD studies suggest 
higher exposures are warranted in the setting of suspected or proven CNS infections. This 
is especially true for neonates and young infants where the risk of CNS infection is high. 
Without larger numbers of patients and better, more reliable outcome measures, linkage 
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of the PK-PD experiments to the clinic remains uncertain. Therefore, carefully designed 
experimental programs coupled with PK-PD bridging studies provide the best way to 
develop new drugs for neonates and infants. 
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Chapter 8 Population Pharmacokinetic of VL-2397, A Novel 
Systemic Antifungal Agent with Activity Against Triazole-
Resistant Aspergillus spp.  
 
Abstract  
Background. VL-2397 is a novel, natural product isolated from Acremonium 
persicinum that has potent in vitro and in vivo fungicidal activity against Aspergillus 
species. The pharmacokinetics from single ascending dose (SAD) and multiple ascending 
dose (MAD) cohorts in a Phase 1 study were combined to construct a population 
pharmacokinetic (PPK) model for VL-2397. 
Methods. Healthy subjects 18 to 55 years of age received single doses of VL-2397 at 
3, 10, 30, 100, 300, 600, and 1200 mg, multiple doses of 300, 600, and 1200 mg for 
7  days, or 300 mg three-times per day for 7 days followed by 600 mg once daily for the 
next 21 days. Plasma samples for analysis were collected throughout the dosing interval. 
PPK model development was performed using Pmetrics (v1.5.1, U of Southern CA). 
Results. A total of 1908 plasma concentrations from 66 subjects were included. The 
drug concentrations over time increased in a less than dose proportional manner for all 
doses above 30 mg. This was further confirmed by plotting dose-normalized 
concentrations over time that did not overlap. A non-linear saturable binding model with 
3 compartments fit the data well. Estimates of clearance increased with dose with mean 
values ranging from 0.4 L/h at 3 mg and 8.5 L/h at 1200  mg. Mean estimated volume in 
the central compartment ranged from 4.8  L to 6.9  L. In the first 24 hours, once daily 
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dosing results in a rapid decrease in plasma concentrations by hour 16 to approximately 1 
mg/L, regardless of dose, with a slow clearance of the molecule over time. 
Administration of 300 mg every 8 hours achieved concentrations above 1 mg/L over an 
entire 24-hour period. There was a significant relationship of body surface area to 
clearance. 
Conclusion. The data suggests that VL-2397 has non-linear saturable binding 
kinetics. Protein binding is the likely primary source of the non-linearity. The PPK model 
can be used to optimize dosing by bridging the kinetics to efficacious pharmacodynamic 
targets. 
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Introduction  
Invasive aspergillosis (IA) is a rapidly life-threatening fungal disease that most 
commonly affects patients with significant immunodeficiency (157). There has been a 
progressive expansion of anti-Aspergillus agents in recent years. Nevertheless, 
suboptimal therapeutic outcomes have resulted from antifungal drug resistance, a limited 
spectrum of antifungal activity, drug toxicity, drug-drug interactions, and 
pharmacokinetic variability (158, 159).  Hence, there is an urgent need to develop new 
antifungal agents with novel mechanisms of action (MOA).  
VL-2397 is a natural product isolated from Acremonium persicinum, strain MF-34733 
that exhibits potent in vitro and in vivo fungicidal activity against medically important 
Aspergillus species (73, 74).  VL-2397 is a hexapeptide with a molecular weight of 915.4 
Da (74). The complex structure resembles ferrichrome, which is a siderophore that 
chelates iron via the siderophore transporter, Sit1 (Figure 26).  
Figure 26 Chemical Structure of VL-2397.  Abbreviations: C=carbon; O=oxygen; 
H=hydrogen; N=nitrogen; Al=aluminum 
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The intracellular target that is ultimately responsible for antifungal activity is not 
known (74, 75). Mammalian cells do not utilize the Sit1 siderophore transporter, which is 
one potential explanation for differential activity in fungi and animals (160).  Thus, VL-
2397 represents an exciting future alternative to overcome some current limitations of 
modern antifungal therapy. 
VL-2397 demonstrates rapid (within the first 2-4 hours) and potent in vitro fungicidal 
activity (MIC90 values ≤ 2 mg/L) against Aspergillus fumigatus (including triazole-
resistant A. fumigatus), A. terreus, A. flavus, A. nidulans, Candida glabrata, C. kefyr, 
Cryptococcus neoformans, and Trichosporon asahii. The agent demonstrates limited in 
vitro activity (MIC90 values ≤ 8 mg/L) against Fusarium solani and does not appear to be 
active (MIC90 values > 16 mg/L) against A. niger, Candida spp. (with the exception of 
C.  glabrata and C. keyfr), Mucorales, Scedosporium apiospermum and Fonsecaea 
pedrosoi. Live cell imaging suggests that VL-2397 causes arrest of hyphal elongation 
(75).  VL-2397 causes dose-dependent prolongation of survival and reduction in fungal 
burden in the lung of immunocompromised mice with invasive pulmonary aspergillosis 
(76). 
A first in human Phase I clinical trial with VL-2397 (VL2397-101) has been 
completed. Herein, we describe the population PK from this study, which was a 
randomized, dose-ranging, double-blind, placebo-controlled study to assess safety, 
tolerability and pharmacokinetics (PK) of intravenous (i.v.) infusion of VL-2397 to 
normal healthy subjects. These data and population PK models provide one of the critical 
steps in defining safe and effective regimens for patients with IA. 
 171 
Methods  
Study Design. An i.v. formulation of VL-2397 was used. The regimens are 
summarized in Table 17. Healthy adults in single ascending dose (SAD) Cohorts 1-7 
received a single dose of VL-2397 ranging from 3 mg to 1200 mg. Subjects in multiple 
ascending dose (MAD) Cohorts 8-10 received multiple dosages of 300, 600, and 1200 
mg once-daily for 7 days, while Cohort 11 received 300 mg every 8 hours (q8h) for 7 
days followed by 600 mg every 24 hours (q24h) for the next 21 days. Infusion times 
varied with each regimen and ranged from 6 to 240 minutes. 
Table 17 Description of Dosage Regimens in SAD and MAD Cohorts with VL-
 2397  
Cohort VL-2397 Dose (mg) Volume 
(mg/mL) 
Infusion Duration (min) Number of Dosing 
Days (days) 
1 3 
0.12 
6 
1 
2 10 20 
3 30 60 
4 100 
1.2 
20 
5 300 60 
6 600 120 
7 1200 240 
8 300 60 
7 
9 600 120 
10 1200 240 
11 300 q8h D1-7, 600 q24h D8-28 60 and 120, respectively 28 
Pharmacokinetic Sampling. Plasma samples from the subjects in the single-dose 
Cohorts 1-7 occurred pre-dose (within 60 minutes prior to the start of the infusion), 
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midway through the infusion, at the end of the infusion, 15 and 30 minutes, and 1, 2, 3, 4, 
6, 8, 12, 24, 36 to 48 hours relative to the start of the infusion. Additional follow-up 
samples were drawn on Days 5 and 11.  
Plasma samples from the subjects in the MAD Cohorts 8-10 occurred pre-dose 
(within 60 minutes prior to the start of the infusion), midway through the infusion, at the 
end of the infusion, 15 and 30 minutes, and 1, 2, 3, 4, 6, 8, 12, and 24 hours (prior to day 
2 dosing) relative to the start of the infusion on Day 1. During the 7-day dosing period, 
plasma samples were collected within 60 minutes prior to dosing on Days 3, 4, 5, and 6. 
On Day 7, samples were collected pre-dose (within 60 minutes prior to the start of the 
infusion), midway through the infusion, at the end of the infusion, 15 and 30 minutes, and 
1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours relative to the end of the infusion. Follow-up 
plasma samples were also collected on Days 11 and 17. 
Plasma sampling for the MAD Cohort 11 occurred on Day 1 pre-dose (within 60 
minutes prior to the start of infusion), midway into the infusion, at the end of the 
infusion, and 3, 7, 8, 11, 15, 16, and 19 hours relative to the end of the first infusion. The 
7- and 8-hour time points were immediately before and after the administration of the 
second dose on Day 1. The 15-and 16-hour time points were immediately before and 
after the administration of the third dose on Day 1. Additional samples were drawn prior 
to the first infusion on Days 2 through 6.  A 24-hour PK profile (pre-dose just prior to the 
start of the infusion, at the end of the infusion, and 3, 7, 8, 11, 15, 16, and 19 hours 
relative to the end of the first infusion on Day 7) was also collected. After day 7, single 
samples were drawn prior to the infusion on days 8 to 10, 15, and 22. A 48-hour profile 
(pre-dose just prior to the start of infusion, midway into the infusion, at the end of the 
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infusion, and at 15 and 30 minutes, and 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours relative to 
the end of the Day 28 infusion) was also collected. Additional plasma samples were 
drawn on Days 32 and 38. 
Bioanalytical Analysis. VL-2397 plasma concentrations were determined using high 
performance liquid chromatography-tandem mass spectrometry (HPLC—MS/MS). The 
analysis was performed by MicroConstants (San Diego, CA, USA). VL-2397 was 
detected in human plasma samples with VL-2397-I.S. (internal standard) and sodium 
heparin (anticoagulant) precipitated using acetonitrile. Samples were vortexed and 
centrifuged. The supernatant was transferred to a clean tube and evaporated under 
nitrogen. The residue was reconstituted and an aliquot was analyzed by reverse-phase 
HPLC using Restek Allure Biphenyl column. The mobile phase was nebulized using 
heated nitrogen in a Z-spray source/interface set to electrospray positive ionization mode. 
The ionized compounds were detected using MS/MS. The dynamic range of the assay 
was 0.002 to 1 mg/L. The lower limit of quantification (LOQ) was 0.002 mg/L. The 
interday precision was below the acceptance criteria (≤15%) and ranged from 4.93 to 
7.24%. The interday accuracy was below the acceptance criteria (≤+15%), ranged from -
1.83 to 0.50%. The intraday precision failed the acceptance criteria of ≤15% (2.63 to 
36.5%). The intraday accuracy passed (≤+20%) at a range of -12.0 to 14.0%. 
Population PK (PPK) Modeling. The plasma concentrations for each cohort were 
plotted versus time to evaluate the concentration-time profiles for each regimen (Figure 
27). To assess for the presence of non-linearity the plasma concentrations for each patient 
were normalized by the daily dose.   
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Figure 27 VL-2397 Plasma concentration versus time over the first 24 hours 
after dosing for all cohorts on a linear (upper) and semi-logarithmic (lower) 
scale.  Mean values (±SD) for each time point at each dosage level are represented by the 
symbols and bars above and below each symbol. Mg doses are represented in the graph, 
MD=multiple dose. 
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The PPK model was developed using nonparametric estimation with Pmetrics 
(v1.5.1, University of Southern California, Los Angeles, CA, USA) (77).  Inspection of 
the plasma concentration over time curves suggested multiple phases of distribution and 
elimination. Therefore, 2, 3, and 4 compartment models were fitted to the data.  These 
multi-compartment linear PK models could not account for the observed non-linear PK. 
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A saturable binding compartment was used to account for the observed non-linearity.  
This compartment accounted for phenomena that may be responsible for the observed 
non-linear PK such as the binding of drug to proteins, drug transporters, or to the 
endothelium. In standard PK models drug in the central compartment is fully mixed and 
is a combination of bound and free drug.  In the model fitted to the VL-2397 data, total 
drug was separated into two distinct compartments.  The central compartment represents 
free unbound drug, while a binding compartment represents bound drug.  Measured drug 
concentrations are the sum of the bound and free compartments divided by the volume of 
the central compartment, i.e. (X(1)+X(3))/V.  
The PK was further complicated by the presence of a prolonged terminal elimination 
phase suggesting an elimination process that was not accounted for by clearance from the 
central compartment.  Therefore, a degradation component was added to the binding 
compartment that represents irreversible loss of drug from that compartment. The 
mathematical formula of the saturable binding model is shown: 
Equation 14  
𝑋𝑃(1) =  𝑅𝐴𝑇𝐸𝐼𝑉(1) − 𝐾𝑐𝑝 ∙ 𝑋(1) + 𝐾𝑝𝑐 ∙ 𝑋(2) − (
𝐶𝑙
𝑉
) ∙ 𝑋(1) − (
𝐾𝑜𝑛
106
) ∙ ((𝑅𝑡𝑜𝑡 ∗ 104) − 𝑋(3))
∙ 𝑋(1) + (
𝐾𝑜𝑓𝑓
106
) ∙ 𝑋(3) − 𝐾𝑐𝑓 ∙ 𝑋(1) + 𝐾𝑓𝑐 ∙ 𝑋(4) 
Equation 15  
𝑋𝑃(2) =  𝐾𝑐𝑝 ∙ 𝑋(1) − 𝐾𝑝𝑐 ∙ 𝑋(2) 
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Equation 16  
𝑋𝑃(3) = (
𝐾𝑜𝑛
106
) ∙ ((𝑅𝑡𝑜𝑡 ∗ 104) − 𝑋(3)) ∙ 𝑋(1) − (
𝐾𝑜𝑓𝑓
106
) ∙ 𝑋(3) − 𝐾𝑑𝑒𝑔 
Equation 17  
𝑋𝑃(4) =  𝐾𝑐𝑓 ∙ 𝑋(1) − 𝐾𝑓𝑐 ∙ 𝑋(4) 
where Kcp, Kpc, Kcf, and Kfc represent first-order intercompartmental rate constants (c, 
central; p, peripheral 2; f, peripheral 3 compartments) with units h-1. Kon and Koff are the 
constants for the rates of association and dissociation, respectively, with units of h-1. 
Because both Kon, Koff, and Rtot values are extreme numbers relative to the other rate 
constants; therefore, to minimize the stiffness in the model each constant and Rtot were 
divided by 106 and multiplied by 104, respectively, to assist program estimation (161). 
Rtot represents the maximum binding and units are moles. Kdeg is a constant in the 
binding compartment (3), which regulates the slow turnover of the binding site and 
irreversible loss of drug from that compartment. 
The PK data were weighted by the inverse of the estimated assay variance. Model 
acceptance was evaluated by visual inspection of the observed-versus-predicted 
concentration values before and after the Bayesian step, the coefficient of determination 
(r2) from the linear regression of the observed-versus-predicted values, and estimates for 
bias (mean weighted error) and imprecision (adjusted mean weighted squared error). 
The Day 1 (24-hour) area under the concentration-time curve (AUC0-24) and Day 
7 (24-hour) AUC144-168 for each subject was calculated using the Bayesian posterior 
parameter estimates from the final model using the trapezoidal rule embedded within 
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Pmetrics. 
Covariate Assessment and Model Building. Parameter estimates, clearance and 
volume, were evaluated against age, sex, weight, body mass index (BMI), body surface 
area (BSA), and race to determine if one or more should be considered for inclusion in 
the structural model. Each continuous covariate (age, weight, BMI, and BSA) was 
evaluated by plotting the variable to the individual parameter. If the confidence interval 
around the slope excluded zero, the covariate was considered to be significant. 
Results  
Study Population. Sixty-six healthy subjects from the 11 cohorts contributed data 
for analysis. The median (range) age, weight, and height were 43 years (range 21-55 
years), 74.2 kg (range 56.5-109.3 kg), and 168.2 cm (146.8-195.1 cm), respectively. The 
majority of patients were Caucasian (53/66; 80%). All subjects completed the dosing 
schedules as planned except for 2 subjects from MAD Cohort 10 (1200 mg) who were 
discontinued early due to adverse events after 1 and 2 doses, respectively. 
Assessment of plasma concentrations versus time. A total of 1908 plasma 
concentrations were included. The drug concentrations over time did not increase 
proportionally with dose. Figure 27 shows plots of the first 24 hours for Cohorts 1-11 in 
the first 24 hours on both a linear and semi-logarithmic scale. Within the first 16 hours, 
the concentrations for the once-daily doses were at or below 1 mg/L and remained at this 
level through the rest of the dosing interval. This suggested a rapid and saturable 
distribution phase.  Figure 28 shows the plasma concentrations-versus-time for each 
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patient after normalizing each by the daily dose. There was minimal overlap of these 
plots suggesting non-linearity, especially above dosages of 30 mg per day.  
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Figure 28 Dose-normalized plasma concentrations-versus-time by cohort (A, B, 
and C). (upper, A) Dose-normalized concentrations over the first 24 hours; Cohorts 1-11. 
(middle, B) Dose-normalized concentrations over time for the single-dose Cohorts 1-7. 
(lower, C) Dose-normalized concentrations over time for the multiple-dose Cohorts (8-
11). Mean values (±SD) for each time point at each dosage level are represented by the 
symbols and bars above and below each symbol. (mg doses are represented in the graph; 
MD=multiple dose). 
A.  
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B.  
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C.   
  
 183 
 
Population Pharmacokinetic Modeling. A non-linear saturable binding model with 3 
compartments fit the data well. The structural model is illustrated in Figure 29. 
Figure 29 Illustration of Structural PPK Non-Linear Saturable Binding 
Model. Structural illustration of the population PK model. Boxes represent the plasma 
compartments (1=central, 2 and 3 are peripheral). The circle represents the binding 
compartment. Arrows demonstrate the flow of drug through the compartments and 
elimination. Abbreviations: Cl: clearance; V: volume in the central compartment; Kcp, 
Kcp, Kpc, Kcd, and Kdc: rate constants for drug moving from the different compartments 
(c, central; p, peripheral; f, third compartment): Kon and Koff: rate constants of 
association and dissociation; Rtot: maximum binding; Kdeg: rate constant regulating 
clearance from the binding compartment. 
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Visual inspection of the observed-versus-posterior predicted concentrations after the 
Bayesian step was acceptable. The coefficient of determination (r2) was 0.987 
(slope  =  1.01 [95% confidence interval 1 to 1.01]) for the linear regression of the 
observed versus predicted mean concentrations (Figure 30). Measures of bias and 
imprecision were also acceptable (-0.124 and 1.04, respectively).  
Figure 30 Observed-versus-predicted concentrations (mg/L) from the best model 
after the Bayesian step (A. population predicted; B. posterior predicted). Upper (A): 
Logistic regression of the observed versus median population predicted plasma 
concentration values. Lower (B): Logistic regression of the observed versus median 
individual posterior predicted plasma concentration values. Dotted line is the line of unity 
where the observed versus predicted values are equal. 
A  
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B  
 
Individual plots for each subjects’ observed and predicted concentrations over time 
showed good predictions by the model (Figure 31). 
  
 186 
Figure 31 Overlay of Observed and Predicted Plasma Concentration Values for 
individual Subjects. Lines represent predicted concentrations and ‘+’ are the observed 
values at each time point for the subject. 
 
 
The estimated model parameters are included in Table 18.   
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Table 18 Median posterior parameter estimates for the best model  
 
Mean Population SD Median Range 
Cl/F (L/h) 5.56 3.57 6.80 0.25-9.95 
V (L) 6.68 2.58 6.10 3.50-14.80 
Kcp (h-1) 2.31 1.75 2.45 0.025-4.98 
Kpc (h-1) 2.86 1.83 2.68 0.04-5.97 
Kon (h-1) 0.57 x 10-6 0.44 x 10-6 0.35 x 10-6 0.008 x 10-6-1.49 x 10-6 
Koff (h-1) 21.01 x 10-6 20.25 x 10-6 10.33 x 10-6 0.35 x 10-6-49.75 x 10-6 
Rtot (mol) 1.79 x 104 1.25 x 104 1.46 x 104 0.52 x 104-3.98 x 104 
Kcf (h-1) 0.50 0.35 0.45 0.06-1.42 
Kfc (h-1) 0.69 0.90 0.22 0.02-2.99 
Kdeg (h-1) 0.010 0.010 0.010 0.0003-0.050 
Abbreviations: Cl: clearance; F: bioavailability; V: volume in the central compartment; Kcp, Kcp, Kpc, Kcf, and Kfc: 
rate constants for drug moving from the different compartments (c, central; p, peripheral; f, third compartment): Kon 
and Koff: rate constants of association and dissociation; Rtot: maximum binding; Kdeg: rate constant regulating 
clearance from the binding compartment. 
The area under the plasma concentration-time curve (AUC) for each dose cohort is 
summarized in Table 19. As illustrated by the dose-normalized plots, AUC did not 
increase in a proportional manner. 
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Table 19 AUC values estimated from the PPK for each Dose Cohort  
 Cohort (dose) AUCinf (mg∙h/L) 
S
in
g
le
-D
o
se
 
1 (3 mg) 27.1 (4.2) 
2 (10 mg) 70.1 (7.6) 
3 (30 mg) 80.8 (24.9) 
4 (100 mg) 83.6 (28.8) 
5 (300 mg) 104.3 (12.8) 
6 (600 mg) 150.6 (17.7) 
7 (1200 mg) 236.0 (46.7) 
M
u
lt
ip
le
-d
o
se
 
Cohort AUC0-24 (mg∙h/L) (Day 1) AUC144-168* (mg∙h/L) 
8 (300 mg) 319.9 (26.5) 133.1 (6.3) 
9 (600 mg) 711.2 (104.5) 206.1 (24.9) 
10 (1200 mg) 1352.1 (801.6) 302.6 (17.7) 
11 (300 mg q8h D1-7; 
600 mg q24h D8-28) 
856.51 (120.0) 1237.2 (127.0) 
*AUC144-168 is only applicable to the multiple dose Cohorts (8, 9, 10, and 11) 
Assessment of covariates. Figure 32 and Figure 33 illustrate the relationship of age, 
weight, BMI, and BSA on clearance and volume, respectively. The only covariate 
relationship found to be significant was BSA on clearance based on linear regression. 
Clearance decreases with increasing BSA (95% confidence interval for the slope was -
 10.19 to -1.61) (Figure 32). There was no relationship between sex and race on 
clearance or volume (p > 0.5). Of note, the low clearance values in the graph are real 
values from the lowest dose cohort (3 mg). 
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Figure 32 Linear regression analysis to describe the relationship of clearance 
and age (upper left), weight (upper right), BMI (lower left), BSA (lower right). Cl vs 
age (Upper left): Slope -0.03 [95% CI -0.12 to 0.07], r2=0.005; p value =0.59. Cl vs 
weight (Upper right): Slope -0.07 [95% CI -0.14 to 0.0002], r2=0.06; p value =0.05. Cl vs 
BMI (Lower left): Slope 0.08 [95% CI -0.28 to 0.43], r2=0.003; p value =0.66. Cl vs BSA 
(Lower right): Slope -5.9 [95% CI -10.2 to -1.6], r2=0.12; p value =0.008. 
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Figure 33 Linear regression analysis to describe the relationship of volume and 
age (upper left), weight (upper right), BMI (lower left), BSA (lower right). V vs age 
(Upper left): Slope -0.02 [95% CI -0.09 to 0.05], r2=0.006; p value =0.53. V vs weight 
(Upper right): Slope 0.05 [95% CI -0.006 to 0.1], r2=0.05; p value =0.08. V vs BMI 
(Lower left): Slope 0.008 [95% CI -0.25 to 0.27], r2=0.000; p value =0.95. V vs BSA 
(Lower right): Slope 2.1 [95% CI -1.15 to 5.42], r2=0.03; p value =0.20. 
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Discussion  
VL-2397 is a systemic antifungal agent that is being developed for the treatment of 
invasive aspergillosis and is one of few agents in development with a novel MOA that 
have the potential to overcome some of the deficiencies of currently licensed agents. 
Non-compartmental analysis of the pharmacokinetic data in this study revealed that VL-
2397 exhibited non-linear pharmacokinetics and neither demonstrated dose 
proportionality nor dose linearity. 
Early in vitro studies using equilibrium dialysis suggested non-linear protein binding 
might be responsible for the non-linearity pharmacokinetics of VL-2397 kinetics 
(unpublished data). This knowledge and evaluation of the raw data led to development of 
a saturable binding compartment and to split the total drug concentration into a free and 
bound compartments. The saturable binding model used was derived from modifications 
to standard Michaelis-Menten terms and target mediated drug disposition models (163). 
While this model did result in a significant improvement in the goodness of fit, it did not 
adequately describe the terminal phase where there was considerable over-prediction of 
the observed concentrations.  To account for this deficiency degradation component was 
added to the binding compartment to represent proteolytic loss of drug.  The addition of 
this loss component improved the goodness of fit and resulted in acceptable predictions.  
The binding compartment at this stage is hypothetical, but based on evidence of saturable 
in vitro protein binding in plasma, and may need to be further confirmed by in vitro 
binding assays. 
In the future, it will be important to better understand the mechanism of the non-
linearity.  This will be especially important for utilizing the PPK model for further dose 
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selection in Phase 2 and 3 clinical studies. An in-depth understanding of protein binding 
in the preclinical models of invasive fungal infections will also be important to ensure 
bridging studies are appropriately designed and interpreted. 
In this study, no significant relationship was found between age, weight, and BMI and 
clearance or volume. Increases in BSA were associated with decreases in clearance. 
In conclusion, in this Phase 1 study in healthy volunteers, VL-2397 demonstrated 
non-linear saturable binding kinetics. Protein binding is likely the primary source of the 
non-linearity. A saturable binding model best described the data. BSA was the only 
covariate with a significant relationship to clearance. The PPK model can be used to 
optimize dosing by bridging the kinetics to efficacious pharmacodynamic targets.  
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Chapter 9 Discussion and Conclusions  
The purpose of this thesis is to utilize different PK-PD techniques to explore 
exposure-response relationships of several antifungal agents. The work starts with 
mathematically linking the time course of isavuconazole drug exposure with the time 
course of response to antifungal therapy measured as changes in biomarker 
concentrations (Chapter 3). In this effort, the recent results of phase 3 clinical trials for 
the same antifungal agent were available to enable validation of the in vivo results. The 
availability of the clinical trials results afforded the opportunity to demonstrate usefulness 
of the in vivo rabbit model and the endpoints utilized for isavuconazole and has 
implications for clinical interpretive breakpoints for Aspergillus spp. Uniquely, it 
provides validation for a path of investigation for future antifungal agents in 
development. Expanding on this work, the GM data from the same isavuconazole clinical 
trial was used to look for early changes in GM that could be used to predict patient 
outcomes and guide therapeutic decisions early in the treatment course (Chapter 4). 
Chapters 5 and 6 focus on the characterization of pharmacokinetic data of isavuconazole, 
evaluating those characteristics in different patient settings, infection types, and 
conditions (e.g. mucositis), and evaluating any potential impact on efficacy. The focus 
then switches to the PK-PD evaluation of the echinocandin antifungal, micafungin, in the 
treatment of neonatal candidiasis (Chapter 7). A population PK model was constructed 
and efficacy data from 2 efficacy trials were combined to provide a linkage from the 
experimental data to the clinic. Chapter 8 provides the first attempt to construct a 
population PK model for a novel investigational antifungal agent, VL-2397, from the 
initial phase 1 healthy volunteer clinical studies. 
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In Chapters 3 and 4, the PD of isavuconazole, was explored using GM as a prognostic 
tool both from an in vivo model and clinical trial. The biomarker, GM, is important 
experimental and monitoring tool in the management of patients with invasive 
aspergillosis. As discussed in Chapter 1, critical steps to establish the clinical utility of 
this biomarker continue to be made. However, more work is needed in patients to better 
define ways of using GMI early in the treatment course to facilitate therapeutic decisions 
that can be beneficial for an individual patient.  As evidence accumulates, it is likely that 
GM will be incorporated into clinical outcome criteria and can therefore be used to assess 
the response to antifungal therapy for future clinical trials. An analysis of serial serum 
GMI in patients with invasive aspergillosis from a phase 3 clinical trial demonstrated that 
increases in GMI in the first week of therapy significantly increase the likelihood of death 
and unsuccessful response. These analyses can be utilized to further validate and 
eventually establish early intervention measures for use during therapy. 
Various intrinsic and extrinsic factors impact the pharmacokinetics of antifungal 
agents. These factors can be explored using population PK-PD techniques to determine if 
exposures and ultimately efficacy are impacted. For antibiotics that rely on thresholds of 
drug concentrations and time above MICs, evaluation of any possible sub-populations or 
conditions that threaten the ability to reach or maintain these thresholds is important to 
ensure adequate therapy. In Chapters 5 and 6, the impact of factors such as disease state 
(type of infection), underlying disease (e.g. hematological malignancy), and other 
medical conditions (e.g. mucocitis) on the PK-PD of isavuconazole are evaluated. In 
these efforts, there were several findings and hypotheses generated. Across the various 
IFD and underlying diseases, isavuconazole clearance and AUC did not differ 
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significantly. PTA analysis allowed for an estimate of the MIC coverage provided by the 
isavuconazole clinical dosing regimen for common fungal pathogens, such as A. 
fumigatus, A. flavus, and A. terreus strains, and the results support previous PTA analyses 
(99) for these organisms. For C. albicans and non-albicans Candida spp., the coverage of 
the isavuconazole MIC distribution from a large collection of in vitro susceptibility 
studies was reasonable. However, the PK characteristics for patients infected with 
invasive candidiasis and candidemia have not been evaluated by the time of this report. 
Given that the recently completed phase 3 clinical trial of the treatment of candidemia did 
not meet the primary endpoint of overall response at the end of the intravenous 
isavuconazole therapy compared to caspofungin (117), characterization of the PK in IC 
patients directly is critical. If different, it could affect the clinical breakpoint selection and 
potentially the recommended dosing regimen for treatment of IC.  
In Chapter 6, patients with slightly lower bioavailability had outcomes similar to 
those with higher bioavailability. Therefore, use of the oral formulation of 
isavuconazonium sulfate during episodes of mucositis may be acceptable; however, 
treating physicians may consider extending isavuconazole intravenous therapy during 
episodes of mucositis or monitoring levels to ensure they are within the range reported 
from the clinical trial. However, additional studies in this population may be warranted. 
In Chapter 7, an effort was made to evaluate linkage between in vivo PK-PD 
experimental findings to the clinic for an area of significant unmet medical need. 
Neonatal candidiasis represents a significant morbidity and mortality burden in affected 
infants (150). Available treatment regimens lack appropriate evidence of treatment effect 
from well-conducted clinical trials. In addition, due to the risk of CNS and organ 
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involvement, dosage regimens are often not established with attention to this nuance in 
the neonatal infection. Micafungin has been tested rigorously experimentally and PK 
bridging studies have established a dosage regimen that does account for the risk of CNS 
disease. However, the attempt to complete a clinical trial with this dosage was 
unsuccessful due to the low incidence of the disease (155). With the available clinical and 
PK data, an exposure-response analysis was performed. While the appropriate target 
exposure was achieved with the target dosage, the analysis did not find a significant 
difference between those infants that achieved the target exposure and those that did not. 
A larger sample size is needed in order to find the true relationship. The study is 
important as it emphasizes the limitations of small numbers, the need for well-
characterized experimental models and PK bridging studies in the absence of large-scale 
clinical trials to establish efficacy and safety. 
Chapter 8 provides the first population PK analysis of the investigational agent, VL-
2397. This compound has demonstrated potent in vitro and in vivo activity against 
Aspergillus spp., including triazole-resistant pathogens. The pharmacokinetics of VL-
2397 are complex. A non-linear saturable binding model provided the best fit to the data. 
The non-linearity appears to stem from non-linear protein binding. A better 
characterization of the mechanism of the non-linearity is important, particularly, for 
utilizing the PPK model for further dose identification in Phase II and III clinical studies. 
An in-depth understanding in protein binding in the preclinical models of invasive fungal 
infections will also be important to ensure bridging studies are appropriately performed 
and interpreted. 
This thesis provides valuable insights into future research opportunities and areas of 
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further understanding. First, in the setting of invasive fungal disease, biomarkers have 
increased the ability to diagnosis infections. Experimentally these same biomarkers are 
utilized successfully to follow the course of an infection and response to antifungal 
therapy. These tools are desperately needed to provide a more objective guide to therapy 
in the clinic. Our data provides a path but requires further validation. This learning brings 
us closer to individualizing therapy to patients. Second, drug development of the next 
group of antifungal compounds will rely more and more on smaller databases. Therefore, 
a heightened emphasis on well-characterized in vitro and in vivo experiments that can be 
utilized to establish exposure thresholds from which PK bridging studies can be used 
from population PK models to ensure adequate dosing regimens. Finally, regulatory 
authorities are increasing their expertize in PK-PD and will continue to increasingly 
expect drug development programs include full PK-PD packages similar to those outlined 
in the EMA guidance. 
In summary, invasive fungal infections result in significant morbidity and mortality 
even with the recent advances in the armamentarium. However, large-scale clinical trials 
to evaluate comparative efficacy and safety when completed do not always address 
questions pertaining to the heterogeneity of the populations in the clinical trials. 
Therefore, PK-PD techniques can assist in that effort. In addition, quite often these 
studies are not feasible due to the low incidence of the specific fungal infections; and 
therefore, evaluation of the antifungal agent in well-characterized in vivo and in vitro 
models followed by human PK bridging studies are essential in the optimization of these 
agents. Effectively combining these tools can be the difference between a successful or 
failed drug development program, or future failure post-market authorization due to 
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resistance development and failure reported in case series. Not to mention proper 
utilization of PK-PD techniques could eliminate some of the increased costs associated 
with the evaluation of multiple dosages in early proof of concept clinical trials. 
Important questions about the appropriate use of antimicrobial therapies can be 
investigated using PK-PD techniques. Providing those that use these agents with an 
enhanced understanding of the amount and duration of a specific compound required to 
treat an infection. The result of these investigations should lead to better patient 
outcomes, decrease in the development of resistance pathogens, and minimizing the risk 
to antibiotic drug development programs due to better optimization of dosing regimens. 
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